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ABSTRACT 
TARGETING NUCLEIC ACID JUNCTIONS USING TRIPTYCENE-BASED 
MOLECULES 
 
Stephanie A. Barros 
David M. Chenoweth 
 Targeting nucleic acids in a structure- or sequence-specific manner with small 
molecules remains a significant challenge in chemical biology. The ability to modulate a 
particular nucleic acid structure would allow for the specific control of cellular processes. 
Nucleic acid junctions are important structural motifs involved in several biological 
processes found in DNA and RNA. Three-way junctions (3WJs) occur at replication 
forks, in triplet repeat expansions, viral genomes, bacterial temperature sensors, as well 
as riboswitches and building blocks in nanotechnology. We have developed a new class 
of nucleic acid junction binders based on the small molecule triptycene. These triptycene-
based molecules were shown to significantly stabilize a model system junction. After 
establishing their selectivity towards junctions over other secondary structures, these 
molecules were applied to biologically relevant junctions. Triptycenes were demonstrated 
to bind to a d(CAG)·(CTG) repeat implicated in the pathogenesis of triplet repeat 
expansion diseases, including Huntington’s disease. These molecules may serve as 
probes to study diseases associated with these repeats. Additionally, we have 
demonstrated that triptycene-based molecules have the ability to modulate the regulatory 
region of the rpoH mRNA, involved in the heat shock response in E. coli. These may 
vii 
 
provide tools to study effects of the heat shock response or as a novel method to target 
pathogens. 
 The synthesis of large libraries of triptycene molecules would allow for rapid 
screening of several biologically relevant junctions. We have developed an effective 
synthesis for bridge-head substituted triptycenes for immobilization on solid support. 
This allows for the synthesis of these molecules using solid phase synthesis. Triptycene is 
a scaffold amenable to diversification, allowing for the development of new small 
molecule probes for the modulation of structure and function of nucleic acid junctions. 
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1.1 Background 
The central dogma of molecular biology provides the flow of genetic information 
within biological systems. In 1958, Francis Crick proposed that the transfer of genetic 
information flows from DNA to RNA to protein.1 The DNA sequence for a particular 
gene serves as a template for its corresponding mRNA by transcription. The mRNA then 
serves as a template for the translation of individual amino acids in a protein. In normal 
cells, the transfer of this information is tightly regulated to maintain balanced levels of 
each component. Cancer cells and other disease-related processes have aberrant 
regulation of the components leading to proliferation. 
 Classically, medicinal chemistry has focused on the design of small molecules 
towards protein targets for potential therapeutic use. Nucleic acids play important roles in 
the regulation of gene expression and gene products through the interaction with ligands, 
such as proteins, enzymes, metabolites, small molecules, and other nucleic acids. The 
ability to target the DNA or RNA encoding a protein involved in a disease state may be a 
useful therapeutic. Targeting disease relevant pathways with small molecules at the DNA 
and RNA level could lead to new therapeutic strategies and deeper biological insight, 
impacting human health. 
1.2 Nucleic Acid Structure 
1.2.1 Deoxyribonucleic acid (DNA) Structure 
Deoxyribonucleic acid (DNA) is a double-helical biopolymer consisting of 
nucleotide monomers composed of a nitrogenous base, deoxyribose sugar, and a 
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phosphate group. Each monomer is connected through a phosphodiester linkage between 
the 2’-deoxyribose rings at the 3’ and 5’ positions. The nitrogenous bases are composed 
of purines [adenine (A) and guanine (G)] and pyrimidines [cytosine (C) and thymine (T)], 
which provide the building blocks of the genetic code.2 The chemical structure of a 
nucleic acid strand is shown in Figure 1.1. Nucleic acids also have two different grooves 
due to helix formation. The DNA major groove is wide and shallow while the minor 
groove is deep and narrow.  
 
 
Figure 1.1. (a) Chemical structure of nucleic acids. (b) Watson-Crick hydrogen bonding between 
base pairs displaying numbering for the bases. 
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The modern history of nucleic acids began in 1951 when Chargaff reported that 
different species contained different base compositions; however the ratio of A and T as 
well as C and G were very similar.3 This is known as Chargaff’s rule and aided Watson 
and Crick in the discovery of the structure of DNA. In 1952, x-ray diffraction data of a 
fiber of DNA was obtained by Rosalind Franklin and Maurice Wilkins.4,5 The diffraction 
data along with Chargaff’s rule led Watson and Crick to propose the base-paired double-
helical model of B-DNA in 1953.6 The model consists of two right-handed helical strands 
oriented in an antiparallel direction with a sugar-phosphate backbone and nitrogenous 
bases positioned inward. The bases occupy the core and are stacked and stabilized by 
hydrogen bonds formed between two paired bases as well as hydrophobic interactions 
(Figure 1.2). Adenine prefers pairing with thymine by two hydrogen bonds and C prefers 
G by three hydrogen bonds. In order to maximize hydrophobic interactions, a helical 
right-handed twist by the sugar-phosphate backbone is required.2 
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Figure 1.2. Comparison of the double helical structures adopted by DNA and RNA. 
The most abundant form of DNA present in nature exists in the B-form, as 
Watson and Crick had observed. However, DNA can adopt other helical conformations. 
B-form DNA has the ability to undergo a conformational change to A-form DNA when 
the relative humidity is reduced to 75%. The right-handed helix in A-DNA is wider and 
flatter compared to B-DNA with a deep major groove and very shallow minor groove.7,8 
In 1979, Andrew Wang and Alexander Rich observed a left-handed double helix formed 
by d(CGCATGCG). This form of Z-DNA is formed in alternating pyrimidine-purine 
sequences and has a deep minor groove and no noticeable major groove.9 A structural 
comparison of the forms of DNA is shown in Figure 1.2 and Table 1.1. 
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Table 1.1. Structural features of DNA and RNA. 
 
1.2.2 Ribonucleic acid (RNA) Structure 
RNA differs from DNA structurally in two ways: the presence of a hydroxyl 
group at the 2’ position of the sugar ring and the absence of a methyl group at the 5 
position of thymidine resulting in uracil (Figure 1.1). Duplex RNA is predominantly 
found in the A-form (Figure 1.2). However, due to the 2’-hydroxyl and that RNA is 
single stranded and folds on itself to increase its stability, various, non-canonical, 
complex three-dimensional structures can be formed. These include bulges and loops of 
various sizes where non-complementary bases are found, as well as hairpins, mismatches, 
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and three- and four-way junctions (Figure 1.3). The 2’-hydroxyl also presents another site 
for hydrogen bonding with water or other regions of the RNA leading to these structures. 
 
 
Figure 1.3. Secondary structures adopted by RNA. 
1.2.3 Higher-Order Structures 
Nucleic acids can adopt several other higher order structures such as triplexes, G-
quadruplexes, and junctions (Figure 1.4). Triplex structures form in homopyrimidine or 
homopurine sequences in both DNA and RNA at specific salt concentrations and pH. The 
third strand in a triple helix binds in the major groove of the duplex forming Hoogsteen 
hydrogren bonds.10,11 G-quadruplexes have the propensity to form in guanine-rich 
sequences either intermolecularly between separate strands or intramolecularly within the 
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same strand (Figure 1.4a). Guanine tetrads are formed when four guanine bases 
Hoogsteen hydrogen bond to form a square planar structure. These tetrads can stack on 
one another forming a G-quadruplex, where strands can be parallel or antiparallel. These 
structures are polymorphic and adopt structures dependent on concentration, sequence, 
and cations.12,13  
 
Figure 1.4. Higher-order nucleic acid structures. (a) Structure of a G-tetrad and an intramolecular 
antiparallel G-quadruplex. (b) Schematic and crystal structure of a four-way junction (PDB: 
1DCW). (c) Schematic and crystal structure of a three-way junction (PDB: 1F44). 
 
DNA junctions serve as important intermediates in several biological processes. Four-
way, or Holliday junctions, are present during homologous recombination, important for 
double-strand break repair and in imparting genetic diversity (Figure 1.4b).14–20  Of 
particular interest is the three-way junction (3WJ), which is formed when three double-
stranded arms come together forming a cavity in the center with an overall Y-shape 
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(Figure 1.4c). Nucleic acid 3WJs are very diverse existing in several different 
conformations with varying numbers of unpaired bases at the center (Figure 1.5). 
Perfectly-paired 3WJs (3H) have been shown to adopt fully extended conformations 
(Figure 1.6a) under a variety of conditions.21 This differs from what has been observed 
for four-way junctions (4WJs) which form coaxial stacked conformations and ion 
dependant folding.22 Nucleic acid 3WJs are ubiquitous structures found throughout 
biological systems (Figure 1.5). The conformations of these junctions have been well-
studied. 
 
Figure 1.5. Examples of important nucleic acid three-way junctions. 
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1.3 Nucleic Acid Junctions 
1.3.1 DNA Three-Way Junctions 
DNA three-way junctions occur in replication and recombination and are also 
present  in viral genomes and polymorphic triplet repeat expansions which are implicated 
in neurodegenerative disease.23–27 DNA 3WJs are diverse, existing as perfectly paired 
(3H) or with unpaired bases at one (3HSn) or more positions (2HSn HSm or HSn HSm HSp) 
at the center of the junction. Using gel electrophoresis, Duckett and Lilley have shown 
that perfectly paired (3H) junctions exist in a fully extended conformation where the 
three angles between the arms are similar (Figure 1.6a).28 This was later confirmed by 
Stuhmeier using FRET experiments, where the three distances measured from one end to 
another of the junction were very similar.29 Shlyakhtenko et al. have carried out 
cyclization experiments and demonstrated that the inter-helical angles ranged between 60 
and 90°.30 Images of perfectly paired 3WJs using atomic force microscopy (AFM) have 
also shown a large compositions of symmetric molecules.31 Additionally, thymine bases 
at the junction are reactive towards osmium tetroxide and ethyl pyrocarbonate in the 
presence and absence of metal cations. This further demonstrates that reactivity with 
these reagents is not precluded by helix-helix stacking and that the junction is folded into 
a more extended Y shape even in the presence of metal cations.28,32 Taken together, these 
experiments demonstrate that there is no coaxial stacking of the helical regions in a 
perfectly paired 3WJ. Some 3H junctions, however, have an asymmetric structure 
depending on the base sequence.33,34 
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Figure 1.6. Conformations of perfectly paired and bulged 3WJs. (a) A perfectly paired three-way 
junction adopting an extended structure. (b) A bulged 3WJ (3HS2) in the extended conformation 
undergoes a conformational change where coaxial stacking is observed in the presence of 
magnesium cations. The angle of the third helix is dependent on the number of unpaired bases. 
Two stacking conformers can be formed. 
 
Due to the unpaired, single-stranded region between the helical arms, 3HSn 
junctions have a higher degree of flexibility compared to 3H junctions. Gel 
electrophoresis studies by Leontis and coworkers, showed that these bulged junctions 
with unpaired nucleotides at the interface form more stable structures.35 Lilley also 
demonstrated that junctions containing unpaired nucleotides adopt a different 
conformation in the presence of metal ions. In the absence of metal ions, the junctions 
assumed an extended conformation in which the inter-helical angles were similar. 
However, in the presence of metal ions, including magnesium and other multivalent ions, 
the junctions underwent an ion-dependent folding transition. Thymine bases at the 
junction were protected against OsO4 reactivity in these folded species. These results 
were consistent with coaxial stacking of two helical arms in the presence of metal ions 
(Figure 1.6b). The angle of the third arm is dependent on the number of unpaired bases.36 
FRET studies later confirmed these observations. Bulge containing 3WJs were found to 
be asymmetrical, where one inter-helical angle was significantly smaller than the other 
two. This angle decreased as the number of unpaired nucleotides increased.29 Time-
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resolved FRET also demonstrated that the structure and flexibility of 3WJs are dependent 
on the number of unpaired bases as well as the base composition of the bulge.37 
Cyclization rates of DNA 3WJs containing unpaired bases were slower than those that 
were perfectly paired.30 NMR studies of 3HS2 DNA junctions in the presence of 
magnesium ions, revealed that two helical arms are coaxially stacked whereas the third 
helix is extended away from the junction.38–41 Two stacking conformers can exist in these 
junctions, depending on the stacking partner. The existence and stability of these 
conformers is dependent on the sequence.42 
1.3.2 RNA Three-Way Junctions 
DNA junctions are important intermediates in biological processes. However, 
RNA junctions occur much more frequently and are often important structural elements. 
They occur in 5S rRNA, 16S rRNA, the hammerhead ribozyme, the group I intron 
ribozyme, viral genomes, bacterial temperature sensors, and telomerase RNA.43–53 
Although the global structure of RNA 3WJs has not been studied as thoroughly as DNA 
junctions, it is thought that the same folding principles from DNA can be applied to 
RNA.54 
There are few examples of perfectly paired (3H) RNA 3WJs in nature. Folding of 
these junctions is difficult while maintaining complete base pairing. This strain is 
released by the addition of unpaired bases at the center of the junction to increase 
conformational flexibility. The structure of several RNA 3WJs have been analyzed to 
gain insight into their folding properties. The 2HS3HS2 junction in the 16S rRNA is the 
binding site for ribosomal protein S15. In the absence of S15 and magnesium, the 
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junction adopts an extended conformation where no coaxial stacking is observed. 
However, upon addition of magnesium, coaxial stacking was observed between two 
arms.44–46 Another example of an RNA 3WJ is the hammerhead ribozyme containing an 
HS1HS7HS3 junction. Coaxial stacking is observed between two stems in crystal 
structures solved.55,56 Other structural studies, including FRET, gel electrophoresis, and 
transient electric birefringence agree well with crystal structures.44,45,57–63 As with other 
junctions, folding is observed upon addition of ions, including magnesium.  
 
 
Figure 1.7. DNA binding small molecules. 
 
Lescoute and Westhof have analyzed structures containing RNA 3WJs in order to 
predict topology and folding of these junctions.64 The junctions were grouped into three 
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families depending on the length of the unpaired segments between the helices. These can 
adopt different conformers just as is observed in DNA junctions. 
1.4 Nucleic Acid Recognition 
1.4.1 Modes of DNA Recognition 
DNA is an attractive target for the development of therapeutics. Mutations in 
DNA sequences may lead to defects in protein function and misregulation leading to 
increases or decreases in cellular processes, which may lead to disease. Many of the 
chemotherapeutic drugs used today are DNA binding agents that cause damage and 
inhibit cellular processes such as replication. These natural products and synthetic small 
molecules generally bind to DNA by few traditional modes of binding.65,66 These include 
intercalation, minor or major groove binding, covalent binding, and interactions with the 
phosphate backbone. Some small molecules rely on more than one binding mode to 
enhance their effectiveness. Examples of DNA binding small molecules are shown in 
Figure 1.7. 
1.4.1.1    Intercalation 
DNA intercalation was first discovered in 1961 when Lerman was studying the 
DNA binding properties of proflavine, a planar, aromatic chromophore.67 Intercalation is 
defined as the full or partial insertion of planar aromatic rings between DNA base pairs in 
either the major or minor groove. The interaction between the DNA and intercalator is 
stabilized by hydrophobic interactions, π-interactions, and electrostatics with the sugar 
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phosphate backbone. The rigidity of the backbone of DNA does not allow for 
intercalation at every base pair. According to the neighbor-exclusion principle, a ligand 
can insert at every other base pair.68 Upon intercalation the DNA helix is partially 
unwound and causes elongation of the helix, which is thought to prevent DNA replication 
and transcription resulting in cell death. Several intercalators have been discovered with 
some examples shown in Figure 1.7. Several well-studied compounds such as acridines, 
anthraquinones, and ethidium bromide are routinely used in molecular biology for the 
staining of DNA. Natural products currently used in the clinic as anticancer drugs include 
actinomycin D and anthracyclines such as doxorubicin. Actinomycin D was isolated in 
1940 and was the first antibiotic to display activity against cancer cells by inhibiting 
transcription.69,70 Doxorubicin was isolated in the 1950s and exhibits its anti-cancer 
activity by intercalating and inhibiting topoisomerase II, thereby preventing relaxation of 
DNA for transcription.71,72 Some of these molecules have the ability to recognize specific 
base pair steps, however this still results in non-specific binding to several DNA 
structures and sequences. 
1.4.1.2    Covalent 
Several alkylating agents have also been developed which covalently bind to 
DNA. Chlorambucil, a nitrogen mustard, covalently modifies DNA by alkylation at the 
N7 of G or A.73 Cisplatin is a very well-known platinum-based drug that covalently binds 
to DNA and is used in the treatment of cancer. As in the case with chlorambucil, cisplatin 
reacts with the N7 of neighboring purines causing a kink in the DNA.74 Other cisplatin 
derivatives have been developed to lower toxicity and increase efficacy. However, these 
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drugs display many side effects due to their non-specificity for cancer cells compared to 
normal cells. 
1.4.1.3    Groove Binding 
Minor groove binders have similar structural features including positive charges 
and aromatic or heteroaromatic rings that form a crescent shape.75 The natural product 
distamycin A binds to the minor groove of DNA with a preference for A,T-rich 
sequences (at least four base pairs of AT). The molecule binds in a 1:1 or 2:1 ratio of 
ligand to DNA.76–78 Distamycin’s specificity and affinity is achieved through hydrogen 
bonding in the minor groove, hydrophobic and electrostatic interactions, and shape 
complementarity. Distamycin has been utilized as an inspiration for the design of minor 
groove binders including polyamides developed by Dervan and coworkers in which a 
combination of pyrrole, imidazole, and hydroxypyrrole can recognize specific DNA 
sequences.79 Several natural products have also been found to interact with the minor 
groove. Anthramycin, part of the pyrrolobenzodiazepine class of natural products, was 
discovered in 1963. Several groups found that these molecules bound to DNA but not 
RNA and that a covalent bond between the ligand and DNA is formed. 80,81 Other minor 
groove binders include diarylamides, such as DAPI and pentamidine, and bis-
benzimidazoles, such as Hoechst 33258. These molecules also bind to A,T rich sequences 
similar to distamycin A.  
Due to the larger width and different hydrogen bonding pattern of the major 
groove of DNA, this region is often targeted by proteins. Helix-turn-helix, zinc-binding, 
and leucine zipper containing proteins provide recognition sites for DNA binding.82 Other 
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oligonucleotides also have the ability to recognize the DNA major groove. These form a 
triple helix by Hoogsteen base pairing. Peptide nucleic acids (PNAs), in which the sugar 
phosphate backbone is replaced with a polyamide, have been utilized for binding as well. 
The decrease in negative charge allows for enhanced binding to the DNA compared to 
another DNA strand.83 Small molecule major groove binders typically exhibit other forms 
of binding such as minor groove binding or intercalation. Nogalamycin is one such 
example where major groove binding is driven by intercalation. 
1.4.2 Targeting RNA with Small Molecules 
RNA was initially considered the messenger between genetic information stored 
in the form of DNA and proteins. However, with the advent of genomic high-throughput 
techniques such as next-generation sequencing, sequencing of the human transcriptome 
has allowed for the detection of thousands of noncoding RNA molecules with various 
functions that are critical in living organisms. These include ribosomal RNA (rRNA) and 
transfer RNA (tRNA) which play crucial roles in protein synthesis, small nuclear RNAs 
(snRNAs) involved in splicing, telomerase-associated RNAs such as TERRA and TERC, 
as well as smaller RNAs including microRNA (miRNA) that participate in RNA 
interference. RNA is also a key component in the progression of infectious disease such 
as HIV and hepatitis C, genetic disease such as Huntington’s or mytonic dystrophy 
characterized by triplet repeat expansions, and metabolic disease including cancer.84–86 
These noncoding RNAs and disease causing RNA motifs may provide new drug targets 
for small molecules. Riboswitches, regulatory regions within an mRNA that bind a small 
molecule regulating gene expression, are also potential drug targets as demonstrated 
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recently by a group at Merck.87 The druggability of RNA is often challenged; however 
one may argue that it has been demonstrated by clinically approved antibiotics which 
bind to ribosomal RNA.  The targeting of a particular RNA would allow for the control 
of specific cellular processes. 
A plethora of natural products have been found to bind to DNA, however fewer 
small molecules are known to bind to RNA. The major groove of A-form RNA is deeper 
and narrower than that of B-DNA and the minor groove is shallower making it more 
difficult to target. Due to RNA’s ability to form complex, three-dimensional structures 
(Figure 1.3) similar to proteins, defined pockets are formed which have the ability to 
interact with other nucleic acids, proteins, and small molecules. These structurally diverse 
binding pockets provide regions for specifically targeting RNA by small molecules.  
The aminoglycosides have been well-studied and used in understanding small 
molecule-RNA binding interactions. (Figure 1.8) This class of molecules binds to cavities 
or pockets in RNA formed from loops, bulges, etc; therefore they have the ability to 
compete with RNA-RNA and RNA-protein interactions. However, they are promiscuous 
binders and will bind to several RNA targets. Nevertheless, studies of aminoglycoside-
RNA interactions provide a platform for the design of new small molecules and are still 
the subject of intense research efforts. 
Electrostatic interactions are important for RNA binding. Generally, molecules 
that interact with nucleic acids contain positive charges which favorably interact with the 
negatively charged biomolecule, increasing the binding affinity. The number of amines 
on aminoglycosides has been shown to correlate to their binding affinity.88 The basicity 
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of the amines can also be tuned, thereby changing the overall charge. It has been 
determined that half of the total binding energy in a number of aminoglycoside-RNA 
interactions is due to electrostatics. Although these interactions are responsible for high 
affinity, they often lead to nonspecific binding.  
Nonionic interactions also contribute to RNA binding. Favorable interactions 
between hydrophobic regions of small molecules and the bases occur, including 
hydrophobic and π-stacking interactions. Hydrogen bonding between molecules and the 
phosphate backbone or nucleobases contribute significantly to binding as well. This has 
also been observed with the aminoglycosides, in which the amine and hydroxyl groups 
act as hydrogen bond donors to the oxygen of the phosphate backbone.89,90 Different 
substitution patterns on small molecules may have distinct interactions with RNA leading 
to enhanced binding affinity. 
Shape complementarity and conformational adaptation also play significant roles 
in small molecule binding to RNA. Shape complementarity is defined as how well a 
molecule and receptor fit both sterically and electrostatically. As discussed previously, 
RNA adopts folds that lead to pockets available for binding. These pockets all differ in 
size and shape as well as electronegativity. This allows for the development of small 
molecules that interact with the RNA with high affinity and specificity. This is observed 
in small molecule interactions with RNA aptamers.91,92 Comformational adaptation is 
defined as conformational changes of the ligand or receptor that occur upon binding. Due 
to the flexibility of RNA, rearrangements can occur upon ligand binding. This may lead 
to nonspecificity as observed with the aminoglycosides. Tor and coworkers designed a 
20 
 
conformationally constrained aminoglycoside to selectively bind the 16S A site over 
TAR RNA. They found that no selectivity was achieved which may be due to the ligand 
adopting a different binding orientation.93 
 
 
Figure 1.8. Structures of the aminoglycosides. 
 
1.4.2.1    Aminoglycosides 
The various antibiotics, including aminoglycosides94, tetracyclines95, and 
oxazolidinones96, that target the ribosome, affecting protein synthesis, are some of the 
best known cases of RNA binders. The aminoglycoside antibiotics contain a large 
number of positive charges and bind to the A-site on the 16S rRNA of bacterial 
ribosomes (Figure 1.8). Binding to the A-site causes a conformational change to adopt an 
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open state which in turn allows for the recognition of noncognate tRNA resulting in 
incorporation of the incorrect amino acid leading to cell death.97,98  
Aminoglycosides also bind to nonribosomal RNA. They have been found to bind 
to tRNA causing a conformational change by displacing a Mg2+ ion and inhibiting amino 
acylation of the tRNA.99,100 Additionally aminoglycosides bind to ribozymes,101,102 
ribonuclease P,103,104 and viral RNAs. In HIV, transcription of viral DNA is aided by the 
trans-activator of transcription (Tat) protein. Tat recognizes a bulged RNA hairpin loop 
known as the trans-activating response (TAR) element present in the beginning of the 
transcript mediated by an arginine-rich area.105–107 Neomycin has been shown to be a 
potent inhibitor of the interaction.108 Triazole-linked neomycin dimers consisting of 
different length linkers were developed displaying increased affinity and specificity.109 
The Rev protein in HIV-1 exports viral RNAs from the nucleus of the host to the 
cytoplasm by binding to the Rev response element (RRE), a stem-loop RNA.105,110 To 
achieve higher affinity and specificity towards RRE, Tor and coworkers have replaced 
the amino groups with guanidinium groups. These ligands displayed a 10-fold increase in 
potency at the inhibition of Rev-RRE compared to the unmodified aminoglycoside. 
Linezolid is the first oxazolidinone to reach the clinic in 2000. Its mechanism of 
action is not completely understood but is thought to act by binding to the 23S rRNA in 
the 50S subunit near the binding site of other antibiotics including chloramphenicol and 
preventing the formation of the initiation complex.96,111 The structural information from 
small molecule binding to the ribosome has been used to design improved compounds. 
22 
 
1.4.2.2    Bulge Binding 
Bulge regions occur in RNA which contain one or more unpaired bases on one 
duplex strand. These can exist as single base bulges, containing one unpaired base, or 
multiple base bulges, in which there is more than one unpaired base. Bulge regions within 
a duplex have a destabilizing effect proportional to the number of unpaired bases.112,113 
TAR RNA contains a bulge region that has been targeted with small molecules frequently 
(Figure 1.9a). 
 
 
Figure 1.9. RNA binding small molecules. (a) Small molecules that bind to the bulge region of 
TAR RNA. (b) Internal loop binders that bind to RRE RNA. (c) Small molecules targeting 
nucleotide repeat expansion. 
 
Several DNA binding molecules including ethidium bromide, berenil, and 
Hoechst 33285 were found to also bind to TAR.114,115 Experiments have shown that 
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Hoechst 33285 prefers binding to the bulge region of TAR, demonstrating a higher 
affinity for the native structure compared to a bulgeless structure.116 Modular ligands 
have also been developed composed of a polyaromatic structure for intercalation, a 
positively charged region to make contacts with the phosphate backbone, and a linker 
connecting the two. One example of these compounds is compound 1 shown Figure 1.8, 
consisting of a 6-chloro-2-methoxy acridine linked to spermidine.117 This molecule binds 
to the bulge region of TAR as demonstrated by RNase footprinting and NMR.118 Other 
conjugated molecules bind to TAR such as ethidium-arginine conjugates which 
researchers have designed to bind to two sites on the RNA.119 Compound 2 has been 
shown to bind to TAR with a Ki of 51 nM. The indole ring intercalates between two base 
pairs while the amines make contacts with the backbone. All of these compounds have 
used intercalation and electrostatic interactions as binding modes. Neocarzinostatin, 3, is 
composed of two ring systems connected by a spirocycle causing a twist in the molecule 
and stacking of the aromatic moieties. This compound was found to bind to various RNA 
bulges including TAR.120 
1.4.2.3    Internal Loop Binding 
 Internal loops occur in regions containing noncomplementary bases. These may 
exist as symmetric loops in which the number of unpaired bases on either side of the 
duplex is the same or unsymmetric when the number of unpaired bases is different. A 
well studied target for internal loop binders is the Rev response element (RRE) (Figure 
1.9b). 
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 In a gel competition assay, several diphenylfuran derivatives were screened for 
the disruption of the Rev-RRE interaction.121 Structure activity relationships (SAR) 
studies were performed to determine the moieties required for binding. From this data 
compound 4 showed the most potency with an IC50 = 0.3 μM. NMR studies demonstrated 
that these ligands bind to the internal loop of the RNA as a dimer through the minor 
groove.122 Marino and coworkers have evaluated several acridine-like molecules towards 
the Rev-RRE interaction. Using a 2-aminopurine assay, they found that acridine orange 
and proflavine had the highest affinity.123 These molecules have led to tight binders but 
are not selective. To achieve selectivity, work has been done to recognize loop regions 
with intercalators displaying the proper hydrogen bonding pattern for the mismatched 
base. Compound 5 was developed to bind to guanine bases and azaquinoline 6 hydrogen 
bonds with adenine mismatches.124,125 Dimers of these molecules have been used to target 
sequence specific mismatches. 
1.4.2.4    Hairpin Loops 
Hairpin loops form when a sequence folds on itself into a duplex connected by 
single stranded bases. This structural motif is one of the most predominant found in 
RNA. In a gel shift assay, compound 7 was identified as a TAR RNA binder (Figure 
1.9a). RNase footprinting experiments and ESI-MS confirmed loop binding to the 
RNA.126 Compound 1 has also been shown to target hairpin loops.127 
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1.4.2.5    Targeting Expanded Repeats 
Nucleotide repeat expansions have become targets for the design of small 
molecules, since these have been associated with several diseases including Fragil X 
Syndrome (SFX)128, Huntington’s disease129, and mytonic dystrophy type I (DM1)130 and 
type II (DM2).131 These repeats [(CTG) or (CCTG)] form a hairpin structure and bind to 
muscleblind-like 1 protein (MBNL1), a regulator of splicing, causing disregulation of 
alternative splicing pre-mRNAs.132 Development of high affinity small molecules may 
displace MBNL1, restoring its function (Figure 1.9c). Zimmerman and coworkers have 
designed a molecule consisting of an acridine DNA intercalator and a triaminotriazine, 
also a known binder. This compound, 8, does not discriminate between d(CTG) and 
r(CUG) repeats, but shows some selectivity towards U-U mismatches.133 Pentamidine has 
also been shown to disrupt the MBNL1 binding to r(CUG) repeats.134 Disney has 
designed compounds in which an alkynyl kanamycin A is assembled on a peptoid 
backbone, 9.135 Another series of these consist of Hoechst 33258, 10.136 This strategy 
uses compounds previously shown to bind to nucleic acids which may lead to 
nonspecificity. 
1.5 Recognition of Nucleic Acid Junctions 
1.5.1 Four-Way Junctions 
Work on targeting 4WJs had began in the late 1980s by Kallenbach when they 
discovered that methidiumpropyl-EDTA-FeII [MPE-FeII], 11, could cleave a Holliday 
junction (Figure 1.10). This compound was found to cleave the junction two to three 
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bases from the branch point. In 2000, Segall and coworkers identified a peptide with the 
sequence WKHYNY that stabilized 4WJs with protein bound. This peptide led to the 
accumulation of 4WJs but did not inhibit recombination.137 A second generation peptide 
with the sequence WRWYCR increased the potency by 50 times and acted as a dimer by 
disulfide formation.138 Based on this dimer, several cyclic peptides were also tested.139 
Searcey, Cardin, and coworkers have targeted 4WJs using bisintercalators with long 
linkers to reach across the junction. Upon crystallization of C6-linked bisacridine-4-
carboxamide, 12, revealed that the acridine displaces an adenine forming a pseudo-base 
pair.140 Recently, Searcey and coworkers have identified a compound, 13, that induces 
the formation of a 4WJ (Figure 1.10).141 
 
 
Figure 1.10. DNA four-way junction binding small molecules. 
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1.5.2 Three-Way Junctions 
Hannon, Coll, and coworkers crystallized a metal complex binding to a DNA 
three-way junction, revealing an alternative mode of binding.142 Hannon and coworkers 
have worked on metallosupramolecular chemistry designing compounds in which three 
bis-pyridylimine ligands wrap around one another in the presence of two Fe2+ ions 
forming two enantiomers, M and P (Figure 1.11a). These ligands have been shown to 
bind to the major groove of DNA causing intramolecular coiling.143,144 Crystallization to 
2.6 Å of the metal complex, [Fe2(C25H20N4)3]Cl4, with a palindromic sequence of DNA 
resulted in the formation of a three-way junction with the complex in the center (Figure 
1.12a). Crystals were only obtained with sequences composed of A-T at the center of the 
junction. Interstingly, the M enantiomer was only observed in the crystal. The 
predominant interactions observed were π-stacking between the central phenylene ring 
and the bases at the junction as well as van der Waals interactions between the end 
pyridine rings and the C5’ sugar. These studies were followed up by NMR145 and 
analysis by gel electorphoresis,146 confirming the ability of the ligand to stabilize 
different 3WJ sequences. Conjugation of arginine to the ends of the metallohelicates, 
increased 3WJ stabilization and showed increased activity in cancer cells.147 However, 
these ligands have also been shown to bind to G-quadruplex DNA as well as double 
helical DNA.148,149 
Monchaud and coworkers have used cationic azacryptands to stabilize DNA 3WJs 
(Figure 1.11b). Several azacryptands were synthesized and tested in a FRET melting 
experiment for thermal stabilization of a 3WJ. These results were compared to a 
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previously studied small molecule, TACN-Q (Figure 1.11c), which had shown some 
selectivity towards 3WJs.150 All compounds reported had the ability to stabilize the 
junction to varying degrees. FRET melting experiments were also performed on duplex 
DNA showing less stabilization compared to 3WJ DNA. Direct melting experiments in 
the presence of G-quadruplex forming DNA, resulted in similar stabilization compared to 
3WJ DNA.151 This is consistent with previous studies on these molecules that have 
shown they interact with G-quadruplexes.152 
 
Figure 1.11. DNA three-way junction binding small molecules. (a) Assembly of Fe(II) triple 
helicate, with M- and P-enantiomers shown. (b) Azacryptands used in studies carried out by 
Monchaud and coworkers. (c) Chemical structure of TACN-Q. 
 
Hannon, Coll, and coworkers have also crystallized the diiron(II) supramolecular 
cylinder with a palindromic RNA sequence to 1.91 Å (Figure 1.12b).153 As they had 
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expected, the cylinder sits in the center of the junction and only the M enantiomer is 
observed. The cylinder also makes contacts at the termini of the arms forming π 
interactions between the bases and the phenyl rings. 
Several differences were observed between the DNA and RNA 3WJs (Figure 
1.12). The DNA junction was found to be cone shaped, where one face of the junction is 
narrower than the other. The two faces of the RNA junction are more similar. Due to the 
absence of a narrow opening, the cylinder may move more freely to maximize π-stacking 
interactions thereby maximizing stabilization. Gel electrophoresis demonstrated that the 
cylinders have the ability to stabilize RNA junctions in solution.153 Interestingly, the M 
and P enantiomers show no difference in binding to the RNA, contrary to what is 
observed with DNA.146  
 
 
Figure 1.12. Comparison of nucleic acid junctions in the present of metallohelicates. (a) DNA 
three-way junction (PDB: 2ET0). (b) RNA three-way junction (PDB: 4JIY). 
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1.6 Triptycene 
The first reported synthesis of triptycene was by Bartlett and co-workers in 
1942.154 This synthesis began with anthracene and p-benzoquinone to yield triptycene in 
6 steps. Wittig and coworkers reported the synthesis of triptycene by a Diels-Alder 
reaction using benzyne and anthracene in 1956.155 Standard routes have been employed 
to access various substitution patterns.156–161 Triptycene belongs to a class of compounds 
called iptycenes composed of phenyl rings fused together by a bicycle[2.2.2]octane 
core.162 Triptycene is the simplest member of this family of compounds, consisting of 
three phenyl rings attached through the bicyclic core. 
 
Figure 1.13. Structure of triptycene. 
 
The unique structure and electro and photochemical properties of triptycene have 
led to its use in a variety of supramolecular and material applications. Triptycene-based 
molecules have been used as ligands for catalysis, as molecular machines, host-guest 
chemistry, gas adsorption, liquid crystals, building blocks in polymers, and many other 
materials chemistry applications.156–158,163–177 However, triptycene has seldom been used 
in biological applications and biomolecular recognition. Analogs have been shown 
promising pharmaceutical properties including anticancer and antimalarial activity.178–180 
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1.7 Overview of Thesis 
The design of DNA and RNA small molecule binders has focused on the 
modification of natural products including the aminoglycosides or the conjugation to 
known binding moieties such as intercalators which often lead to nonspecific binding. 
The ability to target particular nucleic acids in a structure or sequence-dependent manner 
remains a significant challenge.   
As discussed previously nucleic acid junctions are important structural motifs 
found in nature. We were interested in designing a small molecule that would be selective 
towards three-way junctions. Previous 3WJ binders show modest, if any, selectivity 
towards junctions. Additionally many of these molecules require the use of metals. We 
proposed that triptycene provided a scaffold that was 3-fold symmetric with similar 
dimensions to the junction interface. Additionally, triptycene lacks an extended, planar π-
surface area, which will avoid intercalation, and is amenable to diversification in which 
two faces of the molecule can be modified to introduce specificity between junctions. 
This targeting approach is based on shape complementarity. 
Triptycenes were synthesized and the hypothesis was tested using an 
oligonucleotide that formed a 3WJ. These studies demonstrated the triptycene’s ability to 
discriminate DNA 3WJs from double-helical DNA. After establishing this, triptycenes 
were evaluated for binding to d(CAG)·(CTG) trinucleotide repeats implicated in 
neurodegenerative disease. Our studies show that these molecules have the ability to 
modulate the structure of these junctions, which could lead to valuable probes in studying 
these disease-associated repeats. We have also shown that triptycenes can bind to RNA 
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3WJs. The mRNA from the rpoH gene in E. coli, involved in the heat shock response, 
contains a perfectly paired 3WJ at the center, essential for its function. Our studies have 
shown that these molecules can target this piece of RNA and show a decrease in the heat 
shock response in bacteria. Work has also been done to synthesize bridge-head 
substituted triptycenes as building blocks for solid phase synthesis for the generation of 
large libraries. 
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Chapter 2 : Recognition of Nucleic Acid Junction Using Triptycene-Based Molecules 
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2.1 Introduction 
Nucleic acid junctions are ubiquitous structural motifs, occurring in both DNA 
and RNA.1-4 Three-way junctions have been extensively studied by many biophysical 
techniques5-16 and represent important and sometimes transient structures in biological 
processes, such as replication and recombination,17.18 while also occurring in triplet 
repeat expansions, which are associated with a number of neurodegenerative diseases.19.20 
Nucleic acid junctions are ubiquitous in viral genomes and are important structural motifs 
in riboswitches where small molecule modulation holds great potential.21-27 Three-way 
junctions are key building blocks present in many nanostructures,28-31 soft materials,32 
multichromophore assemblies,33,34 and aptamer-based sensors.35-40 In the case of aptamer 
based sensors, DNA three-way junctions serve as an important structural motif. The 
ability to modulate aptamers using specific small molecules represents an important 
challenge for designing nucleic acid sensors, switches and devices.35-40  
Pioneering discoveries by Hannon, Coll and co-workers have demonstrated that 
metal helicates can bind nucleic acid junctions in addition to quadruplexes and helical 
motifs.41-47 Inspiring structural studies have yielded high-resolution details of nucleic acid 
junctions complexed with proteins and metal helicates, providing a starting point for 
rational structure-based design efforts.18,42,47 Given the ubiquity of nucleic acid junctions 
and the potential for many diverse applications, a better understanding of junction 
molecular recognition is needed in addition to an expanded toolbox of small molecule 
probes. Despite the vast number of important nucleic acid targets, we still lack the ability 
to selectively modulate predetermined nucleic acid structures using small molecules with 
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high specificity and affinity beyond a few well-established recognition modes such as 
groove binding.48-51 Small molecule targeting of non-canonical nucleic acid motifs and 
higher-order structures represent an important challenge at the forefront of chemistry and 
chemical biology.52 
Herein, we report a new structure selective triptycene-based scaffold for targeting 
nucleic acid junctions. UV-Vis, circular dichroism (CD), gel shift, and fluorescence 
quenching experiments were used to assess junction recognition properties. We find that 
triptycene-based junction binders exhibit a significant stabilization of perfectly paired 
DNA and RNA three-way junctions.53,54 Further, we report initial cytotoxicity and cell 
uptake data compared to cisplatin, in two human ovarian carcinoma cell lines. 
2.2 Results and Discussion 
Our molecular design began with the recognition that triptycene55,56 possesses a 3-
fold symmetric architecture with dimensions similar to those of the central helical 
interface of a perfectly base-paired nucleic acid three-way junction.18,42,47 Despite the 
occurrence of triptycene in materials applications,57,58 there is a paucity of examples 
where it has successfully been used for biomolecular recognition.59 From our analysis of 
the dimensions of the putative three-way junction binding site, we envisioned that the 
trigonal symmetry and non-planar π-surface of the aromatic rings in triptycene could 
potentially form stacking or buckled base-pair interactions with nucleobases at the 
junction interface, allowing for a shape-selective fit.18,42,47,60 The choice of a non-
intercalative scaffold to minimize nonspecific nucleic acid binding was important to our 
design, and the triptycene structure satisfied this requirement. In previous studies, we 
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have demonstrated that the introduction of geometric and macrocyclic constraints in 
nucleic acid binding small molecules can be used as a strategy to eliminate common 
binding modes such as intercalation and groove binding.61-62 Recently, we reported that 
dimeric azaxanthone (diazaxanthylidene) structures lack the ability to bind B-form DNA 
due to their preference for an anti-folded conformation, despite the DNA binding ability 
of well-known monomeric xanthone intercalators.62 In our previous studies we attributed 
the lack of B-form DNA binding to the discontinuous π-system, caused by the 
overcrowded anti-folded molecular architecture.62 This hypothesis is consistent with the 
architectural requirements for classical intercalator scaffolds, requiring more than one 
ring of continuous planar π-surface area.63 By a similar structural analysis, we expected 
the discontinuous π-surface area of triptycene to rule out classical intercalative binding 
modes. In addition to the shape complementarity and three-dimensional architecture of 
the triptycene scaffold, we were attracted to its modularity and potential for diversity.  
 
Figure 2.1. Triptycene scaffold for targeting nucleic acid three-way junctions. (a) Triptycene in 
the putative binding site of a DNA 3WJ; note the relative sizes. Model complex based on a crystal 
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structure of trimeric Cre recombinase bound to a three-way Lox DNA junction (PDB ID: 1F44). 
18 (b) Structure of triptycene derivatives (Trip 1-3) utilized for targeting nucleic acid junctions. 
 
The triptycene scaffold provides up to 14 positions for diversification, three rings with 
four positions each, and also two bridgehead positions. Triptycene can be described as 
having three buckled π-faces and two threefold symmetric edge faces with a bridgehead 
located at the center of each. These structural attributes of triptycene will become 
important for future studies as we consider the topological differentiation of nucleic acid 
junction faces for achieving sequence specificity and distinguishing DNA from RNA 
junctions. Size comparison of the triptycene core relative to previously reported crystal 
structures of DNA and RNA three-way junctions18,42,47 confirmed our initial hypothesis 
regarding triptycene shape complementarity, prompting us to initiate synthetic efforts 
toward the first rationally designed nucleic acid junction binders based on triptycene 
(Figure 2.1a). We synthesized triptycenes 1-3 (Trip 1-3) and evaluated their ability to 
discriminate a DNA 3WJ from dsDNA, using well-established UV and CD spectroscopic 
techniques. 
UV thermal melting experiments were performed to determine the degree of 
stabilization of Trip 1-3 toward a DNA 3WJ versus dsDNA (Figure 2.2a,b). Triptycenes 
1-3 did not stabilize dsDNA even though a significant stabilization of the DNA 3WJ was 
observed, with ΔTm values of 28.5, 26.3, and 18.5 °C for Trip 1-3, respectively (Figure 
2.2b). Maximum stabilization was achieved after addition of slightly more than one 
equivalent of ligand (Figure 2.21). Triptycene derivatives 1-3 also provide a comparison 
of the effect of positive charge and linker length on junction stabilization. Triptycenes 2 
and 3, where the internal and terminal amines have been removed, demonstrate that the 
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linker length is an important structural parameter to explore in future studies. Despite the 
decreased number of charges in Trip 2 and 3, both compounds retain significant 3WJ-
stabilizing ability (Figure 2.2b). As a further control experiment, stabilization of a DNA 
hairpin corresponding to one of the arms of the junction was evaluated and it showed no 
significant stabilization (Figure 2.25). To further study the impact of the triptycene core, 
compound 4 was synthesized. Compound 4 consists of the minimal repeating structural 
motif embedded in the trimeric architecture of triptycenes 1-3. UV melting analysis with 
4 results in a ΔTm = 2.0 °C for DNA 3WJ and a ΔTm = -1.3 °C for dsDNA (Figure 2.2b). 
This lack of stabilization further demonstrates the unique structure selectivity imparted 
by triptycenes 1-3. Trip 1 was also evaluated against the well studied three-way junction 
(3WJ2) (Figure 2.3).37 The stability of this junction was found to increase by 24.5 ºC in 
the presence of Trip 1. In addition to studies on the stabilization of DNA three-way 
junctions, we have conducted initial studies with RNA three-way junctions. Triptycenes 
1-3 stabilize RNA three-way junctions as demonstrated by UV melting analysis. The ΔTm 
values for stabilization of the RNA 3WJ are as follows: Trip 1 = 12.5 °C, Trip 2 = 2.9 °C, 
and Trip 3 = 3.4 °C (Figure 2.30). Development of RNA-selective junction binders is 
underway and will be reported in due course.  
Circular dichroism (CD) was used to further explore the interaction of Trip 1 with 
the DNA 3WJ (Figure 2.2c and Figure 2.26) The temperature-dependent CD spectra of 
the DNA 3WJ with and without Trip 1 exhibit a maximum at 275 nm and a minimum at 
245 nm centered around 260 nm, which is indicative of the B-DNA helical conformation. 
This CD signature resembles that of other intramolecular nucleic acid junctions.64 As the 
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temperature was increased from 4 °C to 80 °C, the maximum at 275 nm decreased, and 
the minimum at 245 nm became less negative. The temperature-induced change in the 
CD spectrum indicates melting of the DNA 3WJ helical arms. The largest change in the 
spectrum for the DNA 3WJ was observed between 4 °C and 30 °C. In the presence of 
Trip 1, the CD maximum at 275 nm decreased more gradually with increasing 
temperature, which is consistent with the ligand-induced stabilization observed during 
UV experiments. A CD thermal denaturation experiment, in which the molar ellipticity is 
measured at 255 nm as a function of temperature, further demonstrated the dramatic 
stabilization of DNA 3WJ in the presence of Trip 1. The CD melting temperature was 
determined to be 27.4 °C, which is in agreement with the UV thermal denaturation results 
(Figure 2.27). 
 
Figure 2.2. Thermal stabilization data. (a) Representative fraction-folded plot derived from UV 
thermal melting experiments showing significant stabilization of a DNA 3WJ in the presence of 
triptycene 1. Plot was derived using standard fitting procedures. (b) Table of UV thermal 
stabilization data comparing dsDNA and DNA 3WJ. Compound 4 was used to demonstrate the 
unique ability of triptycene to act as a structure-specific core. Hairpin DNA showed no significant 
stabilization in the presence of ligands. (c) Circular dichroism spectra of DNA 3WJ in the 
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absence (left) and presence (right) of triptycene 1. (Sequences of oligonucleotides used in these 
studies are as follows: DNA 3WJ: 5’-CGA CAA AAT GCA AAA GCA TTA CTT CAA AAG 
AAG TTT GTC G-3’, dsDNA: 5’-CCAGTACTGG-3’, Hairpin DNA: 5’-CAA AAT GCA AAA 
GCA TTT TG-3’.) 
 
Gel shift experiments were performed on DNA 3WJ2 to further support junction 
binding by 1 (Figure 2.3). Addition of increasing concentrations of Trip 1 directly to 
DNA 3WJ2 did not result in a measurable shift using a polyacrylamide gel. This indicates 
that there is likely not a nonspecific intercalative binding mode. To further confirm that 
Trip 1 binds the three-way junction, 3WJ2 was incubated with a 12 bp oligonucleotide 
complementary to the 5‘-end of the junction (inhibitor I12). Consistent with the known 
DNA three-way junctions in the literature, faster migration was observed relative to the 
migration of duplex DNA (<25 bp), suggesting the formation of a more compact 3WJ 
structure. Titration of inhibitor I12 results in a slower-migrating band on the gel, 
indicating the formation of a larger complex (Figure 2.3e).  Addition of increasing 
concentrations of Trip 1, results in reformation of the three-way junction and 
displacement of the inhibitor strand (Figure 2.3f). 
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Figure 2.3. Fluorescence quench assay, thermal stability data, and gel shift data. (a) Schematic of 
the competitive oligonucleotide inhibition assay based on fluorescence quenching. (b) Opening 
the three-way junction (3WJ2) with a complementary oligonucleotide (I12). Fluorescence 
increases with an increase in concentration of I12 (RFU = relative fluorescence unit). (c) Closing 
of the three-way junction (3WJ2) and displacement of competitive inhibitor I12 with triptycenes 
1, 2, and 3. Fluorescence decreases with an increase in concentration of triptycene. The observed 
Kd values for Trip 1, 2, and 3 were determined to be 0.221 μM, 0.396 μM, and 5.50 μM, 
respectively. (d) Fraction-folded plot derived from UV thermal melting experiments showing 
significant stabilization in the presence of triptycene 1. (e) Gel shift data showing opening of the 
three-way junction DNA using a complementary oligonucleotide analogous to the fluorescence 
quench in 3b. (f) Displacement of the complementary oligonucleotide and reformation of the 
three-way junction upon titration of triptycene 1. (Sequences of oligonucleotides used in these 
studies are as follows: DNA 3WJ2: 5’-GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG 
GGT CGA CA-3’, Inhibitor strand I12: 5’-TCC TTG TCT CCC-3’, double labeled oligo 
sequence matches that of 3WJ2). 
 
A fluorescence quenching experiment was used to verify binding to the three-way 
junction.37 The 5’- and 3’-ends of a DNA 3WJ-forming oligonucleotide were labeled 
with a fluorophore (FAM) and a quencher (BHQ-1), respectively (Figure 2.3a). Folding 
of the junction brings the 5’ and 3’-ends into close proximity resulting in fluorescence 
quenching. A 12 bp oligonucleotide, complementary to the 5’-end of the junction, was 
used as an inhibitor to stabilize the open state of the junction.37 Addition of Trip 1 to the 
unquenched state of the 3WJ2-I12 complex resulted in a decrease in fluorescence, 
indicating that the ends were brought into close proximity as a result of 3WJ formation. 
The apparent Kd values of the triptycenes were determined to be 0.221 μM for Trip 1, 
0.396 μM for Trip 2, and 5.499 μM for Trip 3 in the fluorescence displacement assay 
(Figure 2.3a-c).  
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Figure 2.4. Cytotoxicity and cell-uptake studies using human ovarian carcinoma cell lines.  (a) 
Percent viability of A2780, a cisplatin-sensitive ovarian cancer cell line, and A2780cis, a 
cisplatin-insensitive ovarian cancer cell line, in the presence of triptycenes 1-3 or cisplatin. 
Viability is shown at a final concentration of 50 μM for each compound. All experiments were 
conducted in duplicate and the asterisk indicates zero viability. (b) Cell-uptake studies using 
MALDI-MS for Trip 1-3 in A2780 cells. Asterisk = no detectible compound. 
 
Initial studies of the cytotoxicity and cell uptake for Trip 1-3 were conducted using 
human ovarian carcinoma cell lines. Previous studies of metallohelicates show diverse 
biological activity41,46,65-71 and cytotoxic effects in cisplatin-resistant A2780cis cell lines. 
This promising result for the metallohelicates led us to conduct initial cytotoxicity studies 
for triptycenes 1-3. Their activity was investigated in human ovarian carcinoma A2780 
cells and the cisplatin-resistant A2780cis cell line using an Alamar blue assay.72 
Significant differences in sensitivity were observed for each of the triptycenes in the two 
cell lines compared to cisplatin (Figure 2.4a). No significant cytotoxic activity was 
observed for triptycene 3 in either cell line. The activity of triptycene 1 was similar to 
that of cisplatin in the A2780 cell line but demonstrated increased cytotoxicity against the 
A2780cis cell line. The highest potency was observed for triptycene 2, with a complete 
loss of cell viability observed for A2780 cells and only 6% viability for A2780cis cells. 
Triptycenes 1-3 show very promising anticancer activity, demonstrating increased or 
similar potency to cisplatin in the cell lines tested. To complement the cell viability 
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studies, we conducted cellular uptake studies in A2780 cells and demonstrate that 
triptycenes can be efficiently internalized within two hours of treatment. Trends in 
cellular uptake parallel our initial cytotoxicity data with the most potent compound Trip 2 
showing the greatest cellular uptake, followed by Trip 1 and Trip 3 (Figure 2.4b). Further 
biological and structure-activity relationship studies are underway and will be reported in 
due course. 
2.3 Conclusions 
In summary, we have rationally designed a new class of non-intercalative 
triptycene-based nucleic acid junction binders. We have demonstrated that triptycene-
based molecules have the ability to recognize both DNA and RNA three-way junctions, 
providing a new versatile scaffold for targeting higher-order nucleic acid structure. Initial 
biological studies show promising cytotoxicity in cisplatin-resistant human ovarian 
carcinoma cell lines and positive cellular uptake. Ongoing efforts in our laboratory are 
directed toward the recognition of both DNA and RNA junctions in addition to the 
development of new classes of structure-specific nucleic acid modulators. Junctions are 
one of the most ubiquitous structural motifs and many exciting opportunities exist for 
developing small-molecule modulators of higher-order structures such as three-way and 
four-way junctions.52,73-84  Small-molecule targeting of noncanonical nucleic acid motifs 
and higher-order structures represent an important challenge at the forefront of chemistry 
and chemical biology with many exciting opportunities. 
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2.4 Material and Methods 
General Methods: DNA 3WJ (5’-CGA CAA AAT GCA AAA GCA TTA CTT 
CAA AAG AAG TTT GTC G-3’), duplex DNA (5’-CCAGTACTGG-3’), DNA 3WJ2 
(5’-GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA CA-3’), and 
DNA hairpin (5’-CAA AAT GCA AAA GCA TTT TG-3’) were purchased from 
Integrated DNA Technologies (IDT). HPLC-purified DNA 3WJ2 oligo modified with a 
5’-FAM and a 3’-BHQ-1 was purchased from IDT. The DNA 3WJ was predicted to have 
a cooperative single inflection melting curve using NUPACK. Trans-
Dichlorobis(triphenylphospine)palladium(II) was purchased from Strem Chemicals, Inc. 
(Newburyport, MA, USA). Sodium hydroxide was purchased from Fisher Scientific 
(Pittsburg, PA, USA). (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate) (HATU) was purchased from GenScript 
(Piscataway, NJ, USA). Benzoic acid was purchased from Acros Organics. All other 
reagents were purchased from Sigma Aldrich (St. Louis, MO, USA) and used without 
further purification. Reactions requiring anhydrous conditions were run under argon with 
solvents purchased from Fisher dried via an alumina column. Silicycle silica gel (55-65 A 
pore diameter) was used for silica chromatography. Thin-layer chromatography was done 
using Sorbent Technologies (Norcross, GA, USA) silica plates (250 µm thickness). Milli-
Q (18 MΩ) water was used for all solutions (Millipore; Billerica, MA, USA). 
1H and 13C NMR were recorded on a Bruker UNI 500 NMR at 500 and 125 MHz, 
respectively. Matrix-assisted laser desorption ionization (MALDI) mass spectra were 
obtained on a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA, 
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USA) using α-cyano-4-hydroxycinnamic acid (CHCA). Low resolution electrospray 
ionization (ESI) mass spectra (LRMS) were collected on a Waters Acquity Ultra 
Performance LC (Milford, MA, USA). High resolution mass spectra were obtained at the 
Univeristy of Pennsylvania Mass Spectrometry Center on a Micromass AutoSpec 
electrospray/chemical ionization spectrometer. Ultraviolet absorption spectroscopy and 
thermal denaturation experiments were performed on a JASCO V-650 spectrophotometer 
(JASCO Analytical Instruments; Easton, MD, USA) equipped with a JASCO PC-734R 
multichannel Peltier using quartz cells with 1 cm path lengths. High-performance liquid 
chromatography was performed on a JASCO HPLC (Easton, MD, USA) equipped with a 
Phenomenx (Torrance, CA, USA) column (Luna 5µ C18(2) 100A; 250 x 4.60 mm, 5 µm) 
using aqueous (H2O + 0.1% CF3CO2H) and organic (CH3CN) phases. Circular 
dichroism experiments were performed on an Aviv 410 CD spectrometer (Aviv 
Biomedical; Lakewood, NJ, USA) using a 0.1 cm path length quartz cuvette. 
Fluorescence measurements were collected on a Tecan M1000 plate reader (Mannedorf, 
Switzerland). 
HPLC chromatograms were obtained at all wavelengths from 200 to 800 nm 
(bottom plot). 254 and 214 nm were chosen as virtual channels to show the absorbances 
at those two specific wavelengths (top plot). The blue line corresponds to 254 nm and the 
red line corresponds to 214 nm (top plot). The lamps used were D2 + W with a slit width 
of 4 nm. A flow rate of 1.00 mL/min was used over 30 minutes. The method began at 10 
% acetonitrile and 90 % water + 0.1 % TFA. The gradient was slowly increased to 100 % 
acetonitrile. 
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Synthesis: 
 
 
Trimethyl 9,10-dihydro-9,10-[1,2]benzenoanthracene-2,7,15-tricarboxylate (6).  
2,7,15-triiodo-9,10-dihydro-9,10-[1,2]benzenoanthracene (5) was synthesized according 
to the literature.85 To a solution of 5 (23.6 mg, 0.037 mmol) in anhydrous DMF (0.5 mL) 
was added PdCl2(PPh3)2 (1 mg, 0.0014 mmol), Et3N (27.2 mg, 0.27 mmol) and CH3OH 
(0.2 mL). The solution was stirred under CO (150 psi) in a Parr apparatus at 60 °C for 14 
hours. The reaction mixture was concentrated under vacuum and purified by column 
chromatography on silica gel with 30 % dichloromethane/hexanes. The product was 
isolated as a yellow solid (15.9 mg, 0.037 mmol, 60%). 1H NMR (500 MHz, CDCl3) δ 
8.07 (s, 3 H), 7.76 (dd, 3 H, J = 7.7, 1.4), 7.48-7.46 (d, 3 H, J = 7.7), 5.62 (s, 1 H), 5.59 
(s, 1 H), 3.87 (s, 9 H); 13C NMR (500 MHz, CDCl3) δ 166.77, 148.52, 144.80, 128.01, 
127.96, 124.98, 124.12, 54.29, 53.74, 52.26; HRMS m/z calcd for C26H19O6- [M-H]- 
427.1187, observed [M-H]- 427.1201.  
 
 
9,10-dihydro-9,10-[1,2]benzenoanthracene-2,7,15-tricarboxylic acid (7). To a solution 
of 6 (9.6 mg, 0.019 mmol) in dioxane (0.2 mL) was added 1 M NaOH (0.2 mL) and 
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heated to 45 °C for 2 hours. Dioxane was removed under vacuum, diluted with water and 
extracted with CH2Cl2. The aqueous phase was acidified with 1 M HCl to pH 2 and the 
solution was extracted with EtOAc. The organic phase was dried over Na2SO4, and 
concentrated under vacuum to leave 7 (7.1 mg, 0.018 mmol, 95%) as a white solid. 1H 
NMR (500 MHz, MeOD) δ 8.10 (d, 3 H, J = 1.4), 7.76 (dd, 3 H, J = 7.7, 1.6), 7.55 (d, 3 
H, J = 7.7), 5.82 (s, 1 H), 5.80 (s, 1 H), 13C NMR (500 MHz, MeOD) δ 169.58, 150.37, 
146.61, 129.61, 128.97, 125.85, 125.01, 55.11, 54.57; HRMS m/z calcd for C23H13O6- 
[M-H]- 385.0718, observed 385.0725. 
CO2H
CO2H
HO2C
1. HATU, DIEA, DMF
H2N N NHBoc
N
H
N NH2
R =
2. 4 M HCl, dioxane
7
1
O R
R
OR
O
 
 
N2,N6,N14-tris(3-((3-aminopropyl)(methyl)amino)propyl)-9,10-dihydro-9,10-
[1,2]benzenoanthracene-2,6,14-tricarboxamide (1). To a solution of 7 (7 mg, 0.018 
mmol) in DMF (0.2 mL) was added HATU (24 mg, 0.063 mmol) and DIEA (15.5 mg, 
0.12 mmol) and was stirred at room temperature for 5 min. Tert-butyl (3-((3-
aminopropyl)(methyl)amino)propyl)carbamate86 (15.5 mg, 0.063 mmol) was added and 
stirred overnight. The reaction mixture was concentrated under vacuum, then diluted with 
water and extracted with EtOAc. The organic phase was dried over Na2SO3 and 
concentrated. The crude product was suspended in 4 M HCl in dioxane and stirred for 2 
hours. The mixture was concentrated, redissolved in acidic water (0.1 % TFA) and 
washed with CH2Cl2. Product was purified on a JASCO High-Performance Liquid 
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Chromatography (HPLC) instrument on a C18 column using aqueous (H2O + 0.1 % 
TFA) and organic (CH3CN) phases. . 1H NMR (500 MHz, D2O) δ 7.87 (s, 3 H), 7.60 (d, 
6 H), 5.92 (s, 1 H), 5.89 (s, 1 H), 3.45-3.44 (m, 6 H), 3.31-3.17 (m, 12 H), 3.09-3.06 (t, 6 
H), 2.89 (s, 9 H), 2.16-2.03 (m, 12 H); 13C NMR (500 MHz, D2O) δ 170.55, 147.95, 
145.03, 131.01, 125.19, 124.34, 122.54, 117.46, 115.14, 112.82, 53.97, 52.86, 52.69, 
39.54, 36.59, 36.38, 23.83, 21.87; HRMS m/z calcd for C44H66N9O3+ [M+H]+ 768.5283, 
observed 768.5291. 
 
 
N2,N6,N14-tris(7-aminoheptyl)-9,10-dihydro-9,10-[1,2]benzenoanthracene-2,6,14-
tricarboxamide (2). To a solution of 7 (4.5 mg, 0.012 mmol) in DMF (0.2 mL) was 
added HATU (14.2 mg, 0.037 mmol) and DIEA (9.0 mg, 0.070 mmol) and was stirred at 
room temperature for 5 min. tert-butyl (7-aminoheptyl)carbamate87 (8.5 mg, 0.037 mmol) 
was added and stirred overnight. The reaction mixture was concentrated under vacuum, 
then diluted with water and extracted with EtOAc. The organic phase was dried over 
Na2SO3 and concentrated. The crude product was suspended in 4 M HCl in dioxane and 
stirred for 2 hours. The mixture was concentrated, redissolved in acidic water (0.1 % 
TFA) and washed with CH2Cl2. Product was purified on a JASCO High-Performance 
Liquid Chromatography (HPLC) instrument on a C18 column using aqueous (H2O + 0.1 
% TFA) and organic (CH3CN) phases. 1H NMR (500 MHz, D2O) δ 7.80 (s, 3 H), 7.60 (d, 
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3 H, J = 7.8), 7.46 (dd, 3 H, J = 7.7, 1.4), 5.90 (s, 1 H), 5.79 (s, 1 H), 3.35 (t, 6 H, J = 
6.9), 2.91 (t, 6 H, J = 7.5), 1.61-1.58 (m, 12 H), 1.34 (m, 18 H); 13C NMR (500 MHz, 
D2O) δ 169.20, 147.55, 144.77, 131.30, 124.15, 117.56, 115.24, 39.91, 39.362, 28.62, 
27.91, 26.65, 26.00, 25.48; HRMS m/z calcd for C44H63N6O3+ [M+H]+ 723.4956, 
observed 723.4964. 
 
 
N2,N6,N14-tris(3-(dimethylamino)propyl)-9,10-dihydro-9,10-[1,2]benzenoanthracene-
2,6,14-tricarboxamide (3). To a solution of 7 (4.2 mg, 0.011 mmol) in DMF (0.2 mL) 
was added HATU (13.2 mg, 0.035 mmol) and DIEA (8.7 mg, 0.068 mmol) and was 
stirred at room temperature for 5 min. N1,N1-dimethylpropane-1,3-diamine (8.7 mg, 
0.035 mmol) was added and stirred overnight. The reaction mixture was concentrated 
under vacuum, then diluted with water and extracted with EtOAc. Organic phase was 
dried over Na2SO3 and concentrated. The crude product was suspended in 4 M HCl in 
dioxane and stirred for 2 hours. The mixture was concentrated, redissolved in acidic 
water (0.1 % TFA) and washed with CH2Cl2. Product was purified on a JASCO High-
Performance Liquid Chromatography (HPLC) instrument on a C18 column using 
aqueous (H2O + 0.1 % TFA) and organic (CH3CN) phases. . 1H NMR (500 MHz, D2O) δ 
7.77 (d, 3 H, J = 1.6), 7.48 (d, 3 H, J = 7.8), 7.42 (dd, 3 H, J = 7.8, 1.7), 5.77 (s, 1 H), 
5.73 (s, 1 H), 3.42-3.39 (t, 6 H, J = 6.7), 3.13-3.10 (m, 6 H), 2.82 (s, 18 H), 2.00-1.94 (m, 
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6 H); 13C NMR (500 MHz, D2O) δ 170.22, 147.81, 144.91, 130.92, 125.1, 124.26, 
122.52, 117.47, 55.26, 42.63, 36.48, 24.16;  MALDI m/z calcd for C38H51N6O3+ [M+H]+ 
639.4017, observed 639.326. 
 
 
N-(3-((3-aminopropyl)(methyl)amino)propyl)benzamide (4). To a solution of benzoic 
acid (10 mg, 0.082 mmol) in DMF (0.2 mL) was added HATU (37.4 mg, 0.098 mmol) 
and DIEA (23.3 mg, 0.18 mmol) and was stirred at room temperature for 5 min. Tert-
butyl (3-((3-aminopropyl)(methyl)amino)propyl)carbamate (24.1 mg, 0.098 mmol) was 
added and stirred overnight. The reaction mixture was concentrated under vacuum, then 
diluted with water and extracted with EtOAc. Organic phase was dried over Na2SO3 and 
concentrated. The crude product was suspended in 4 M HCl in dioxane and stirred for 2 
hours. The mixture was concentrated, redissolved in acidic water (0.1 % TFA) and 
washed with CH2Cl2. Product was purified on a JASCO High-Performance Liquid 
Chromatography (HPLC) instrument on a C18 column using aqueous (H2O + 0.1 % 
TFA) and organic (CH3CN) phases. . 1H NMR (500 MHz, D2O) δ 7.82 (d, 2 H, J = 8.0), 
7.70-7.67 (m, 1 H), 7.61-7.58 (m, 2 H), 3.58-3.56 (m, 2 H), 3.40-3.37 (m, 2 H), 3.29-3.27 
(m, 2 H), 3.15 (t, 2 H, J = 7.7), 2.97 (s, 3 H), 2.20-2.13 (m, 4 H); 13C NMR (500 MHz, 
CDCl3) δ 171.35, 133.29, 132.38, 128.89, 127.05, 54.03, 52.97, 39.68, 36.57, 36.48, 
23.94, 21.94. HRMS m/z calcd for C14H24N3O+ [M+H]+ 250.1914, observed 250.1923. 
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Figure 2.5. UV absorption spectra. (a) UV absorption for triptycene 1. (b) UV absorption for 
triptycene 2. (b) UV absorption for triptycene 3. (c) UV absorption for compound 4. 
 
HPLC Analysis: 
 
 
Figure 2.6a. Solvent gradient for analytical HPLC chromatograms. 
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Figure 2.6b. Analytical HPLC chromatogram of Trip 1. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
 
 
Figure 2.6c. Analytical HPLC chromatogram of Trip 2. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
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Figure 2.6d. Analytical HPLC chromatogram of Trip 2. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
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Figure 2.7. 1H NMR of triptycene 6 in CDCl3. 
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Figure 2.8. 13C NMR of triptycene 6 in CDCl3. 
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Figure 2.9. 1H NMR of triptycene 7 in MeOD. 
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Figure 2.10. 13C NMR of triptycene 7 in MeOD. 
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Figure 2.11. 1H NMR of Trip 1 in D2O. 
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Figure 2.12. 13C NMR of Trip 1 in D2O. 
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Figure 2.13. 1H NMR of Trip 2 in D2O. 
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Figure 2.14. 13C NMR of Trip 2 in D2O. 
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Figure 2.15. 1H NMR of Trip 3 in D2O. 
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Figure 2.16. 13C NMR of Trip 3 in D2O. 
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Figure 2.17. 1H NMR of compound 4 in D2O. 
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Figure 2.18. 13C NMR of compound 4 in D2O. 
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DNA 3WJ design: 
 
  
Figure 2.19. (a) Minimum free energy structure of DNA 3WJ designed using NUPACK. (b) 
Predicted melting curve generated by NUPACK.88 
 
Melting temperature analysis: An aqueous solution of 10 mM potassium 
cacodylate (CacoK), pH 7.2 was used as analysis buffer. DNA 3WJ, dsDNA, and DNA 
hairpin were brought to a final concentration of 1 μM and 2 μM, respectively. Samples 
were heated to 90 °C for 5 min, cooled to room temperature slowly, then to 4 °C. 
Samples were incubated for 1 hour at room temperature with 3 µL of ligand at a final 
concentration of 4 μM for DNA 3WJ. The concentration of the ligand was 8 μM for 
dsDNA. Denaturation was recorded at 260 nm from 5 °C to 90 °C with a heating rate of 
0.5 °C min-1. Upper and lower baselines were used to plot the fraction folded.89  
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Figure 2.20. UV thermal stabilization data for 1 in 10 mM CacoK, pH 7.2. (a) Normalized plot 
from UV thermal melting experiment with DNA 3WJ at 1 µM in the absence (black) and 
presence of 1 (red). (b) Fraction folded plot for DNA 3WJ at 1 µM in the absence (black) and 
presence of 1 (red). (c) Normalized plot from UV thermal melting experiment with dsDNA at 2 
µM. (d) Fraction folded plot for dsDNA in the absence (black) and presence (red). 
 
 
 
Figure 2.21. UV thermal stabilization data for 1 at different concentrations in 10 mM CacoK, pH 
7.2. (a) Normalized plot from UV thermal melting experiment with DNA 3WJ at 1 µM in the 
absence (black) and presence of 1 at 1, 2, and 4 equivalents (blue, green red, respectively). A 
double inflection is observed with 1 equivalent of 1, indicating that the compound is not 
completely bound. (b) Fraction folded plot for DNA 3WJ at 1 µM in the absence (black) and 
presence of 1 at 2 and 4 equivalents (green and red, respectively).  
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Figure 2.22. UV thermal stabilization data for triptycene 2. (a) Normalized plot from UV thermal 
melting experiment with DNA 3WJ at 1 µM in the absence (black) and presence of 2 (red). (b) 
Fraction folded plot for DNA 3WJ and 2. (c) Normalized plot from UV thermal melting with 
dsDNA at 2 µM in the absence (black) and presence of 2 (red). (d) Fraction folded plot for 
dsDNA and 2. 
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Figure 2.23. UV thermal stabilization data for triptycene 3. (a) Normalized plot from UV thermal 
melting experiment with DNA 3WJ at 1 µM in the absence (black) and presence of 3 (red). (b) 
Fraction folded plot for DNA 3WJ and 3. (c) Normalized plot from UV thermal melting with 
dsDNA at 2 µM in the absence (black) and presence of 3 (red). (d) Fraction folded plot for 
dsDNA and 3. 
 
81 
 
 
 
Figure 2.24. UV thermal stabilization data for control 4. (a) Normalized plot from UV thermal 
melting experiment with DNA 3WJ at 1 µM in the absence (black) and presence of 4 (red). (b) 
Fraction folded plot for DNA 3WJ and 4. (c) Normalized plot from UV thermal melting with 
dsDNA at 2 µM in the absence (black) and presence of 4 (red). (d) Fraction folded plot for 
dsDNA and 4. 
82 
 
 
Figure 2.25. UV thermal stabilization data for triptycenes 1, 2, and 3 with a DNA hairpin. (a) 
Normalized plot from UV thermal melting experiment with DNA hairpin at 1 µM in the absence 
(black) and presence of 1 (red). (b) Fraction folded plot for DNA hairpin and 1. (c) Normalized 
plot from UV thermal melting with DNA hairpin at 1 µM in the absence (black) and presence of 
2 (red). (d) Fraction folded plot for DNA hairpin and 2. (a) Normalized plot from UV thermal 
melting experiment with DNA hairpin at 1 µM in the absence (black) and presence of 3 (red). (b) 
Fraction folded plot for DNA hairpin and 3. 
 
Circular Dichroism: DNA was suspended at 20 µM in 10 mM CacoK, pH 7.2 
and annealed by heating to 90°C for 5 min, cooled to room temperature slowly, then to 4 
°C. Spectra were measured every 0.5 nm between 350 nm and 190 nm with a 5 s 
averaging time. Samples were incubated at each temperature for 20 minutes prior to scan.  
 A 50 µM solution of DNA was prepared in 10 mM CacoK, pH 7.2 and annealed 
by heating to 90°C for 5 min, cooled to room temperature slowly, then to 4 °C, for CD 
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melting. Samples were incubated with ligand (200 µM) at room temperature for 1 hour. 
The CD melting experiment was measured at 255 nm using a 1 °C step and a 2 min 
equilibration time. The averaging time was 15 s. All CD spectra were buffer corrected 
and converted to molar ellipticity.  
 
 
 
Figure 2.26. Temperature-dependant CD spectra. CD spectra of 20 µM DNA 3WJ in 10 mM 
CacoK, pH 7.2 at different temperatures of DNA 3WJ in the absence (a) and presence (b) of 
triptycene 1.  
  
 
 
Figure 2.27. CD thermal experiment. (a) CD spectra of 50 µM DNA 3WJ in 10 mM CacoK, pH 
7.2 in the absence (black) and presence of 1 (red). (b) Molar ellipticity at 255 nm as a function of 
temperature. Thermal analysis was run with 50 µM DNA 3WJ with (red) and without (black) 1. 
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Figure 2.28. CD spectra of 20 µM DNA 3WJ2 in 10 mM CacoK, pH 7.2  at 4 °C. 
 
 
 
Figure 2.29. UV thermal stabilization data for triptycene 1. (a) Normalized plot from UV thermal 
melting experiment with DNA 3WJ2 at 1 µM in the absence (black) and presence of 1 (red). (b) 
Fraction folded plot for DNA 3WJ2 and 1.  
 
Figure 2.30. UV thermal stabilization data for triptycenes 1, 2, and 3. (a) Normalized plot from 
UV thermal melting experiment with RNA 3WJ2 at 1 µM in the absence of ligand (black) and in 
the presence of 1 (blue), 2 (green), and 3 (red). (b) Fraction folded plot for RNA 3WJ2 at 1 µM in 
the absence of ligand (black) and in the presence of 1 (blue), 2 (green), and 3 (red). RNA 
sequence: 5’-GGCACAAAUGCAACACUGCAUUACCAUGCGGUUGUGCC-3’. 
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Gel Shift Assay: The inhibitor strand titration gel was run by incubating aptamer 
(0.25 μM) with increasing concentrations of inhibitor strand in a 20 μL solution in 50 
mM sodium phosphate buffer, pH 7.0 at room temperature for 1 hour. Samples for 
compound titration were prepared by incubating aptamer (0.25 μM) with inhibitor strand 
(0.25 μM) for 1 hour followed by titration of 1 and incubated at room temperature for 1 
hour. Samples were run on a 15% non-denaturing polyacrylamide gel (19:1 
monomer:bis) at 50V in 1X TBE buffer at 4 °C for 5 hours. Gels were stained with SYBR 
Gold for 10 minutes and visualized using a BioRad GelDoc XR+ imager.  
Fluorescence quenching experiments: All binding experiments were conducted 
in 50 mM sodium phosphate buffer, pH 7.0. Fluorescence measurements were recorded 
with excitation at 495 nm and emission at 520 nm using 5 nm bandwidths. Inhibitor 
strand binding curves were obtained by adding 1 μL of increasing concentrations of 
inhibitor strand to 19 μL of 120 nM aptamer. Samples were incubated for 1 hour and ran 
in triplicate in a 384-well plate. Inhibitor strand displacement curves were obtained by 
incubating 120 nM aptamer with 1 μM inhibitor 12 for 1 hour, followed by addition of 
increasing concentrations of 1. Samples were incubated for 1 hour and measured in 
triplicate. 
Cell Culture and Cytotoxicity: All cell lines were maintained in a humidified 
incubator at 37 °C in 5% CO2. A2780 and A2780cis cells were cultured in RPMI 1640 
(Corning Cellgro) supplemented with 10% fetal bovine serum (Giboc, Life 
Technologies), 1% L-glutamine (Corning Cellgro), penicillin and streptomycin (Corning 
Cellgro). Cells were seeded at a density of 2,000 cells/well in culture media (50 μL) in 
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384-well plates 24 hours prior to treatment. Cells were treated with DMSO (vehicle 
control), doxorubicin (positive control, 10 μM final), cisplatin (50 μM to 25 nM), or 
triptycenes (50 μM to 25 nM) for 72 hours at 37 °C with 5% CO2. DMSO concentrations 
were kept at 1%. Alamar blue (5 μL) was added and incubated for 4 hours. Fluorescence 
was measured at 590 nm. The vehicle control was taken as 100% cell viability and 
doxorubicin was taken as 0% viability.  
Cellular Uptake by MALDI90,91: A2780 cells were grown as described above. 
Cells were diluted to 250,000 cells/mL in fresh media. Cells (2 mL) were treated with 
DMSO (vehicle control) or triptycenes (50 μM final) for 2 hours at 37 °C with 5% CO2. 
DMSO concentrations were kept at 1%. The cells were centrifuged at 640g for 2 minutes. 
The supernatant was removed and the cells were washed with 500 μL of 50 mM Tris-
HCl, pH 7.4 three times. The supernatant was placed in a clean microcentrifuge tube for 
MALDI analysis. The cell pellet was suspended in lysis buffer (0.3% Triton-X-100, 100 
mM NaCl) and heated to 100 °C for 15 minutes. The lysate was centrifuged at 7080g for 
5 minutes and the supernant was transferred to a clean microcentrifuge tube. MALDI was 
used to analyze the washes and lysate using α-cyano-4-hydroxycinnamic acid as the 
matrix. 
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Figure 2.31: Cell uptake studies using MALDI-MS. Cells were incubated with triptycenes for 2 
hours, pelleted, washed with buffer three times to remove extracellular compound, and then 
lysed. Column 1: Spectra for Trip 1. (a) Spectrum of Trip 1 from wash 1. A m/z = 768.203 was 
observed for the triptycene. (b) Spectrum of Trip 1 from wash 2. The mass of Trip 1 is still 
present at a lower intensity. (c) Spectrum of Trip 1 from wash 3. The mass is no longer observed. 
(d) Spectrum of the lysate of cells incubated with Trip 1, showing an m/z corresponding to the 
desired mass. (e) Cell lysate in which no triptycene was added, demonstrating that the mass is not 
observed in normal cell lysates. Column 2: Spectra for Trip 2. (f) Spectrum of Trip 2 from wash 
1. A m/z = 723.781 was observed for the triptycene. (g) Spectrum of Trip 2 from wash 2. The 
mass of Trip 2 is no longer present. (h) Spectrum of Trip 2from wash 3. (i) Spectrum of the lysate 
of cells incubated with Trip 2, showing an m/z corresponding to the desired mass. (j) Cell lysate 
in which no triptycene was added, demonstrating that the mass is not observed in normal cell 
lysates. Column 3: Spectra for Trip 3. (k) Spectrum of Trip 3 from wash 1. A m/z = 639.550 was 
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observed for the triptycene. (l) Spectrum of Trip 3 from wash 2. The mass of Trip 3 is still present 
at a lower intensity. (m) Spectrum of Trip 3 from wash 3. The mass is no longer observed. (n) 
Spectrum of the lysate of cells incubated with Trip 3. The desired mass is not observed 
demonstrating that Trip 3 was not taken up into the cells. (o) Cell lysate in which no triptycene 
was added, demonstrating that the mass is not observed in normal cell lysates. 
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Chapter 3 : Triptycene-based small molecules modulate (CAG) · (CTG) repeat 
junctions 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under Creative Commons (CC BY 3.0). 
From: S. A. Barros, D. M. Chenoweth. Triptycene-based small molecules modulate 
(CAG)·(CTG) repeat junctions. Chem. Sci.2015, 6, 4752-4755. Copyright The Royal 
Society of Chemistry 2015. 
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3.1 Introduction 
Nucleic acid junctions play important roles in biological processes and serve as 
key structural motifs in nanotechnology and aptamer-based sensing applications.1-9 In 
biology, three-way junctions (3WJs) are found as transient intermediates during 
replication, recombination, and DNA damage repair.10,11 Junctions are also present in 
several viral genomes, such as HIV-1, HCV, and adeno-associated virus in addition to 
playing key roles in viral assembly. 12-18 Nucleic acid junctions are also prevalent in the 
emerging field of DNA and RNA nanotechnology where the bacteriophage phi29 pRNA 
containing RNA three-way junctions provide a particularly impressive example.15-18 
Furthermore, they occur in trinucleotide repeat expansions found in unstable genomic 
DNA associated with neurodegenerative diseases.19-21 The development of structure and 
sequence-specific nucleic acid binding molecules remains an important challenge in 
chemical biology.22-30 The ability to target specific motifs using small molecules would 
allow for the precise control of biological processes and the possibility of modulating 
disease states.  
DNA trinucleotide repeats are present throughout the genome. Expansions of 
these repeats, however, are associated with a number of neurodegenerative diseases, 
including Huntington’s disease, spinobulbar muscular atrophy, and myotonic 
dystrophy.31-33 Current models of triplet repeat expansion disease suggest slippage during 
DNA synthesis by the formation of dynamic DNA hairpin structures. As the length of the 
repeat increases, the growing hairpin structure gains thermodynamic stability, with repeat 
length providing an important positively correlated diagnostic for disease severity.31-33 
97 
 
Slipped-out (CAG)n·(CTG)n repeats have been implicated in the pathogenesis of triplet 
repeat expansion diseases such as Huntington’s disease and several others.19-21,31-33 These 
“slipped-out” regions are dynamic and occur along the duplex, forming three-way 
junctions. Current models suggest that one arm of the junction contains the excess repeats 
while the other arms maximize complementary pairing between adjacent strands. A 
dynamic ensemble of conformations are possible at the slipped junction interface, where 
base pairing interactions differ with each state. The slipped-out (CAG)n repeat in Figure 
3.1 has been shown to contain one unpaired base at the center of the junction. Previous 
NMR studies have demonstrated that this sequence can adopt a multitude of 
conformations, where dynamic single nucleotide bulges at the junction interface 
interconvert between structures.21 Small molecule probes could provide important tools 
for gaining molecular level insight into the dynamics and repair processes associated with 
trinucleotide repeat junctions; however, probes of this kind are currently unknown. 
 
 
Figure 3.1. Slipped DNA junctions formed by (CAG)·(CTG) repeats. Licensed under CC BY 
3.0. 
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Recently, we reported a new class of triptycene-based three-way junction (3WJ) 
binders.34 Here, we apply the triptycene scaffold as a first step toward developing new 
tools to recognize trinucleotide repeat junctions. We assessed the ability of our new 
triptycene based molecules to modulate the structure of d(CAG)n repeats using gel shift, 
fluorescence quenching, and circular dichroism (CD). 
3.2 Results and Discussion 
Utilizing a well-studied (CAG)·(CTG) repeat sequence known to form slipped-
DNA three-way junctions, we developed a competitive inhibitor-based gel shift assay. 
This assay was inspired by previous work from our laboratory and seminal studies from 
the Plaxco and Ricci laboratories.9,34 We utilized the junction forming (CAG)·(CTG) 
repeat sequence (TNR) and an inhibitor strand (I10) shown in Figure 3.2a. The optimal 
inhibitor strand was 10 base pairs long and complementary to the 5’-end of the junction. 
Titration of inhibitor strand I10 into the folded junction resulted in a concentration 
dependent supershift of the band corresponding to hybridization of the TNR junction 
with I10, forming a larger molecular weight complex (TNR-I10) (Figure 3.2b). Addition 
of small molecules capable of binding the TNR junction leads to I10 strand displacement 
from the TNR-I10 complex in a concentration dependent manner (Figure 3.3a).  
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Figure 3.2. (a) Schematic of gel shift assay. (b) The folded TNR 3WJ was incubated with 
different concentrations of an inhibitor strand (I10) complementary to the 5’-end, resulting in 
formation of TNR-I10. Non-denaturing polyacrylamide gel ran in 1x TBE at 4 °C. Licensed 
under CC BY 3.0. 
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Figure 3.3. (a) Schematic of gel shift assay. The folded TNR 3WJ was incubated with an 
inhibitor strand complementary to the 5’-end, opening the junction structure (TNR-I10). Addition 
of triptycene results in reformation of the junction (TNR-Trip). (b) Structures of triptycene 
derivatives (Trip 1-4). (c) Gel shift assay where TNR-I10 was incubated with triptycene 
derivatives at a constant concentration. (d) A plot of the difference in band intensities of TNR 
and TNR-I10. Bars below zero in the plot indicated an increased amount of complex relative to 
3WJ. (e) Gel shift assay in the presence and absence of Trip 3 and Trip 4. Samples contained 0.5 
μM TNR alone (where minus sign is indicated) or 0.5 μM TNR and 1.5 μM I10 (where a plus 
sign is indicated). Increasing concentrations of Trip 3 were added (lane 3, 0 μM; lane 4, 0.01 μM; 
lane 5, 0.10 μM; lane 6, 0.50 μM; lane 7, 1.0 μM; lane 8, 5.0 μM) and Trip 4 (lane 11, 0 μM; lane 
12, 0.01 μM; lane 13, 0.10 μM; lane 14, 0.50 μM; lane 15, 1.0 μM; lane 16, 5.0 μM; lane 17, 10.0 
μM). Lanes 1 and 9 are loaded with a 25 base pair DNA ladder in which the band present 
corresponds to 25 bases. Free TNR junction and TNR-I10 complex are indicated. Non-
denaturing polyacrylamide gel ran in 1x TBE buffer at 4 °C. Licensed under CC BY 3.0. 
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Inspired by nucleic acid binding proteins, we synthesized a new class of 
triptycene molecules containing amino acids commonly found at the protein-nucleic acid 
interface. Analysis of these interfaces reveals an abundance of positively charged amino 
acid residues such as arginine, lysine, and histidine. We synthesized triptycene 
derivatives substituted with arginine, lysine, and histidine (Trip 2-4) as shown in Figure 
3.3b. Compounds 2-4 were assessed using a competitive displacement gel shift assay and 
compared to Trip 1, which was previously shown to significantly stabilize 3WJs (Figure 
3.3c). Folded TNR 3WJ was incubated with I10, followed by addition of triptycenes 1-4 
at the same concentration. Triptycenes 1-4 were able to reform the junction to varying 
degrees (Figure 3.3c,d). Trip 3 and Trip 4 were the most effective, while Trip 1 was 
slightly less effective and Trip 2 did not show reformation of the junction. Interestingly, 
addition of Trip 1 and Trip 2 resulted in a slower moving band on the gel, indicating 
formation of a higher order structure. Trip 3 and Trip 4 resulted in the most significant 
inhibitor (I10) displacement, shifting TNR-I10 to the TNR-Trip complex and reforming 
the junction. A full titration of Trip 3 and Trip 4 with pre-incubated TNR-I10 was then 
performed (Figure 3.3e). Concentration dependent displacement of the inhibitor strand 
(I10) resulted in reformation of the junction. 
Next, we tested the ability of Trip 3 and 4 to induce fluorescence-quenching upon 
junction formation using a double labelled (CAG)·(CTG) repeat oligonucleotide. The 
TNR oligonucleotide was labelled with a FAM fluorophore on the 5’-end and an 
IowaBlack quencher on the 3’-end (TNR*) (Figure 3.4a). Formation of the junction 
results in little to no fluorescence due to the proximity of the quencher and fluorophore, 
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resulting in efficient contact quenching. The junction was incubated with the 10 bp 
inhibitor strand (I10). As expected, titration of I10 resulted in an increase in fluorescence, 
consistent with disruption of the folded junction, in which the fluorophore and quencher 
are separated in space (TNR*-I10) (Figure 3.4b). Pre-formation of the open inhibited 
state of the junction (TNR*-I10) followed by titration of Trip 3 or Trip 4, resulted in a 
concentration dependent decrease in fluorescence (Figure 3.4c). The decrease in signal 
indicates that the fluorophore and quencher are in close proximity due to refolding of the 
junction. Due to the competitive nature of this assay, only apparent Kd values are 
reported. The apparent Kd values of Trip 3 and Trip 4 were determined to be 52.8 nM and 
2.36 μM, respectively. 
 
 
Figure 3.4. Fluorescence-quenching assay and circular dichroism (CD). (a) TNR 3WJ was 
labeled with a fluorophore and quencher. When folded, low fluorescence is observed. Addition of 
inhibitor I10, opens the junction resulting in an increase in fluorescence (TNR*-I10). Addition of 
triptycene, reforms the junction, resulting in quenching of fluorescence. (b) Titration of I10 to the 
folded junction results in an increase in fluorescence. Fluorescence assay was conducted in 50 
mM sodium phosphate buffer at pH 7.2. (c) Titration of Trip 3 and Trip 4 to TNR*-I10 results in 
a decrease in fluorescence. (d) Temperature-dependent circular dichroism of the TNR junction. 
Temperature-dependent CD in the presence of Trip 3 (e) and Trip 4 (f). Circular dichroism 
measurements were conducted in 50 mM sodium phosphate buffer at pH 7.2. Licensed under CC 
BY 3.0. 
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Temperature-dependent circular dichroism (CD) was used to further characterize 
the interaction of Trip 3 and Trip 4 with the TNR junction. The CD spectra are indicative 
of B-DNA, showing  positive signals at 280 nm due to base stacking and negative signals 
at 250 nm due to the right-handed helicity (Figure 3.4d-f).35  As the temperature 
increased, the positive at 280 nm decreased and the negative at 250 nm increased, 
consistent with melting of the DNA structure (Figure 3.4d). Upon addition of Trip 3 and 
Trip 4, distinct spectral changes are observed, resulting in an increased signal at 240 nm 
as well as a more positive signal at 280 nm and more negative signal at 210 nm (Figure 
3.4e,f). The increase at 280 nm is consistent with enhanced base stacking and increased 
helicity. Studies have shown that CAG slip-outs in a 3WJ are less paired and adopt more 
of an open loop structure.36-38 The increased helicity observed in the CD spectrum may be 
due to increased base pairing interactions in the slip-out region upon addition of Trip 3 or 
4.  
3.3 Conclusions 
In summary, we have described triptycene-based molecules that binds to 
d(CAG)·(CTG) trinucleotide repeats. Trip 3 and Trip 4 bind to a model (CAG)·(CTG) 
repeat as determined by gel shift and fluorescence-quenching experiments. The CD 
spectra are also consistent with enhanced helicity of the slipped out junction upon 
addition of Trip 3 and 4. This new class of nucleic acid binding small molecule may 
serve as inspiration for creating valuable probes for diseases associated with trinucleotide 
repeat expansions. Trinucleotide repeat nucleic acid sequences are associated with a large 
number (>30) of inherited human muscular and neurological diseases. The trinucleotide 
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repeat tract length is dynamic and often correlates with disease severity, where short 
stable tracts are commonplace in the non-affected population. Longer unstable triplet 
repeat tracts are more prone to expansion as opposed to contraction, in addition to being 
predisposed to generational transmission.33 Trincleotide repeat repair outcomes are also 
affected by structural features present in slipped sequences, where the structure may 
determine which proteins are recruited for repair.39-46 Stabilization of a particular 
structure could lead to altered repair of slipped-out junction. Addition of ligands that bind 
to these junctions may affect repair outcomes as well as recruitment of proteins. Small 
molecule probes will provide valuable tools to study these processes. Small molecule 
binding and stabilization or modulation of these dynamic structures could lead to the 
development of therapeutic agents for their associated diseases.  
3.4 Material and Methods 
General Methods: TNR DNA 3WJ (5’-
GCGGAGCAGCCCTTGGGCAGCACCTTGGTGCTGCTCCGC-3’) and DNA inhibitor 
10 (5’-GCTGCTCCGC-3’) were purchased from Integrated DNA Technologies (IDT). 
HPLC-purified TNR DNA 3WJ oligo modified with a 5’-FAM and a 3’-IowaBlack was 
purchased from IDT.  Amino acids (Boc-Arg(Mtr)-OH, Boc-Lys(Boc)-OH, and Boc-His-
OH were purchased from Merck Millipore Novabiochem (Billerica, MA, USA). (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate) (HATU) was purchased from GenScript (Piscataway, NJ, USA). 
All other reagents were purchased from Sigma Aldrich (St. Louis, MO, USA) and used 
without further purification. Reactions requiring anhydrous conditions were run under 
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argon with solvents purchased from Fisher dried via an alumina column. Thin-layer 
chromatography was done using Sorbent Technologies (Norcross, GA, USA) silica plates 
(250 µm thickness). Milli-Q (18 MΩ) water was used for all solutions (Millipore; 
Billerica, MA, USA). 
1H and 13C NMR were recorded on a Bruker UNI 500 NMR at 500 and 125 MHz, 
respectively. Matrix-assisted laser desorption ionization (MALDI) mass spectra were 
obtained on a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA, 
USA) using α-cyano-4-hydroxycinnamic acid (CHCA). Low resolution electrospray 
ionization (ESI) mass spectra (LRMS) were collected on a Waters Acquity Ultra 
Performance LC (Milford, MA, USA). High resolution mass spectra were obtained at the 
University of Pennsylvania Mass Spectrometry Center on a Waters LC-TOF mass 
spectrometer (model LCT-XE Premier) using electrospray ionization in positive or 
negative mode, depending on the analyte. High-performance liquid chromatography was 
performed on a JASCO HPLC (Easton, MD, USA) equipped with a Phenomenx 
(Torrance, CA, USA) column (Luna 5µ C18(2) 100A; 250 x 4.60 mm, 5 µm) using 
aqueous (H2O + 0.1% CF3CO2H) and organic (CH3CN) phases. Circular dichroism 
experiments were performed on a JASCO J-1500 CD Spectrometer (Easton, MD, USA) 
using a 0.1 cm path length quartz cuvette. Fluorescence measurements were collected on 
a Tecan M1000 plate reader (Mannedorf, Switzerland). HPLC chromatograms were 
obtained at all wavelengths from 200 to 800 nm (bottom plot). 254 and 214 nm were 
chosen as virtual channels to show the absorbances at those two specific wavelengths 
(top plot). The blue line corresponds to 254 nm and the red line corresponds to 214 nm 
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(top plot). The lamps used were D2 + W with a slit width of 4 nm. A flow rate of 1.00 
mL/min was used over 35 minutes. The method began at 10 % acetonitrile and 90 % 
water + 0.1 % TFA. The gradient was increased to 25 % acetonitrile over 25 minutes and 
then increased to 100% acetonitrile. 
Synthesis: 
General Procedure: To a solution of 57 (0.08 mmol) in DMF (1 mL) was added 
HATU (0.256 mmol) and DIEA (0.496 mmol) and was stirred at room temperature for 5 
minutes. The corresponding amino acid (0.256 mmol) was added and stirred overnight. 
The reaction mixture was concentrated under vacuum, then diluted with water and 
extracted with EtOAc. The crude product was suspended in 4M HCl in dioxane and 
stirred for 2 hours. The mixture was concentrated, dissolved in acidic water (0.1% TFA) 
and washed with CH2Cl2. The product was purified on a JASCO High-Performance 
Liquid Chromatography (HPLC) instrument on a C18 column using aqueous (H2O + 
0;1% TFA) and organic (CH3CN) phases.  
 
(2S,2'S,2''S)-N,N',N''-(9,10-dihydro-9,10-[1,2]benzenoanthracene-2,7,15-triyl)tris(2-
amino-5-guanidinopentanamide) (2). 1H NMR (500 MHz, D2O) δ 7.65 (s, 3 H), 7.51-
7.50 (d, 3 H) 7.12-7.10 (d, 3 H), 5.72 (s, 1 H), 5.66 (s, 1 H), 4.13-4.10 (t, 3 H), 3.23-3.20 
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(t, 3 H), 2.03-1.98 (m, 6 H), 1.72-1.66 (m, 6 H); HRMS m/z calcd for C38H56N15O33+ 
[M+3H]3+ 256.8225, observed 256.8231. 
 
 
 
(2S,2'S,2''S)-N,N',N''-(9,10-dihydro-9,10-[1,2]benzenoanthracene-2,7,15-
triyl)tris(2,6-diaminohexanamide) (3). 1H NMR (500 MHz, D2O) δ 7.65 (s, 3 H), 7.52-
7.50 (d, 3 H) 7.13-7.11 (d, 3 H), 5.73 (s, 1 H), 5.67 (s, 1 H), 4.11-4.09 (t, 3 H), 2.99-2.96 
(t, 6 H), 2.01-1.96 (m, 6 H), 1.17-1.67 (m, 6 H), 1.51 (m, 6H); HRMS m/z calcd for 
C38H54N9O3+ [M+H]+ 684.4344, observed 684.4357. 
 
 
(2S,2'S,2''S)-N,N',N''-(9,10-dihydro-9,10-[1,2]benzenoanthracene-2,7,15-triyl)tris(2-
amino-3-(1H-imidazol-5-yl)propanamide) (4). 1H NMR (500 MHz, D2O) δ 8.58 (s, 3 
H), 7.65 (s, 3 H) 7.54-7.52 (d, 3 H), 7.40 (s, 3 H), 7.07-7.05 (d, 3 H), 5.75 (s, 1 H), 5.69 
(s, 1 H), 4.40-4.36 (t, 3 H), 3.47-3.45 (d, 6 H); 13C NMR (500 MHz, D2O) δ 166.63, 
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145.73, 142.70, 134.65, 133.19, 126.72, 124.29, 118.65, 118.15, 117.52, 115.20, 52.93, 
51.60, 26.58; MALDI-TOF m/z calcd for C38H38N12O3 [M+H] 710.80, observed 711.397, 
HRMS m/z calcd for C38H39N12O3+ [M+H]+ 711.3263, observed 711.3274. 
 
HPLC: 
 
Figure 3.5a. Analytical HPLC chromatogram of Trip 2. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
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Figure 3.5b. Analytical HPLC chromatogram of Trip 3. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
 
 
Figure 3.5c. Analytical HPLC chromatogram of Trip 4. HPLC chromatograms were obtained at 
all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were used to show 
absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
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Figure 3.6. 1H NMR of Trip 2 in D2O. 
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Figure 3.7. 1H NMR of Trip 3 in D2O. 
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Figure 3.8. 1H NMR of Trip 4 in D2O. 
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Figure 3.9. 13C NMR of Trip 4 in D2O. 
 
114 
 
Gel Shift Assay: All gel shift experiments were conducted in 50 mM sodium 
phosphate buffer, pH 7.2. The screening gel was run by incubating TNR 3WJ (0.5 μM) 
with inhibitor strand 10 bases long (1.5 μM) in a 20 μL solution at room temperature for 
2 hours. Triptycenes were then added at a final concentration of 10 μM and incubated for 
2 hours. Samples were run on a 20% non-denaturing polyacrylamide gel (19:1 
monomer:bis) at 50V in 1X TBE buffer at 4 °C for 10 hours. Gels were stained with 
SYBR Gold for 10 minutes and visualized using a BioRad GelDoc XR+ imager. 
Inhibitor strand titration gel was run by incubating TNR 3WJ (0.5 μM) with 
increasing concentrations of inhibitor strand in a 20 μL solution at room temperature for 
2 hours. Samples for compound titration were prepared by incubating TNR 3WJ (0.5 
μM) with inhibitor strand (1.5 μM) for 2 hours followed by titration of Trip 4 and 
incubation at room temperature for 2 hours. Samples were run on a gel as described 
above.  
Fluorescence quenching experiments: All binding experiments were conducted 
in 50 mM sodium phosphate buffer, pH 7.2. Fluorescence measurements were recorded 
with excitation at 495 nm and emission at 520 nm using 5 nm bandwidths. Inhibitor 
strand binding curves were obtained by adding 1 μL of increasing concentrations of 
inhibitor strand to 19 μL of 120 nM TNR 3WJ. Samples were incubated for 2 hours and 
ran in triplicate in a 384-well plate. Inhibitor strand displacement curves were obtained 
by incubating 120 nM aptamer with 1 μM inhibitor 10 for 2 hours, followed by addition 
of increasing concentrations of 4. Samples were incubated for 2 hours and measured in 
triplicate. 
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Circular Dichroism: DNA was suspended at 6 µM in 50 mM sodium phosphate 
buffer, pH 7.2 and annealed by heating to 90°C for 5 min, cooled to room temperature 
slowly, then to 4 °C. Spectra were measured every 0.5 nm between 350 nm and 200 nm 
with an 8 s averaging time. Samples were incubated at each temperature for 20 minutes 
prior to scan. Samples were incubated with ligand (24 µM) at room temperature for 1 
hour. All CD spectra were buffer corrected and converted to molar ellipticity.  
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4.1 Introduction 
Temperature is a universal stress for all living organisms and a rapid response to 
temperature fluctuation is essential for cell survival. The heat shock response (HSR) is a 
cellular process characterized by an increase in the synthesis of a set of heat shock 
proteins (HSPs) in response to stress, such as increases in temperature.1,2 The HSR in 
Escherichia coli is regulated by an alternative σ factor, σ32, encoded by the rpoH gene. 
An increase in temperature from 30 °C to ≥37 °C results in increased synthesis and 
stability of σ32, leading to transcription of σ32-dependent genes involved in the HSR.3-11  
Translational control is a common strategy for modulation of the HSR in both 
eukaryotes and prokaryotes. Morita and coworkers have found that the σ32 mRNA 
secondary structure acts as a thermosensor, crucial for the induction of σ32, in the 
Escherichia coli HSR pathway (Figure 4.1).12-16 Intramolecular base pairing interactions 
in the first 229 nucleotides controls the translation efficiency of σ32 (Figure 4.1b). 
Analysis of a series of deletions and mutations shows the presence of two regulatory 
elements that fold into a complex structure, preventing initiation of translation at low 
temperatures. The first regulatory element is a 15-nucleotide downstream box (region A) 
near the AUG start codon allowing for binding of the 30S ribosome. The second 
regulatory element is stem III which blocks the downstream box (Figure 4.1b). The AUG 
start codon is then blocked by nucleotides present in stem I. Base-pairing of the start 
codon and downstream box by stems I and III prevents ribosome binding at low 
temperatures. Toeprinting experiments have demonstrated that stress conditions disrupt 
the RNA secondary structure, leading to ribosome binding and increased translation.15 
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These experiments directly correlate the degree of ribosome binding to RNA stability. 
Small molecule probes with the ability to stabilize the RNA structure could be useful for 
the study of the effects of the HSR as well as potential antibacterial agents. 
 
Figure 4.1. (a) Brief schematic for the heat shock response in E. coli and strategy for small 
molecule modulation at the mRNA level. (b) Schematic showing the overall secondary structure 
of the 5’-end of the σ32 mRNA regulatory element. Important regions are shown with the boxed 
area corresponding to the AUG start codon. 
 
Chemical and enzymatic probing of the 5’-end of the mRNA reveals that the 
regulatory regions (region A and region B) within the RNA structure form a perfectly 
paired three-way junction (3WJ).16 Recently, we developed a new class of junction 
binders based on a triptycene scaffold.17,18 Here, we report small molecules based on 
triptycene that are able to modulate the stability of the σ32 mRNA. We determined the 
ability of these ligands to modulate the structure of σ32 RNA using UV thermal melting, 
circular dichroism (CD), and fluorescence quenching. Additionally, we demonstrate in 
vivo modulation of the heat shock response using a σ32-GFP fusion protein reporter 
system in E. coli. 
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4.2 Results and Discussion 
We initiated our studies with a model system corresponding to the regulatory junction 
present in the rpoH mRNA (Figure 4.2). UV melting experiments were performed to 
determine the ability of Trip 1 and 2 (Figure 4.2a-c) to stabilize the model system. In the 
absence of ligand, the RNA melted at 51.6 °C. Thermal stabilization was observed in the 
presence of Trip 1 and 2 with ΔTm values of 11.3 and 13.7 °C, respectively (Figure 2c). 
Circular dichroism (CD) was also performed to investigate the interaction of Trip 1 and 2 
with the RNA. CD spectra of the model system in the presence and absence of Trip 1 and 
2 at 4°C are consistent with A-form RNA, displaying a maximum at 266 nm, a large 
minimum at 210 nm and a smaller minimum around 240 nm (Figure 4.3). As the 
temperature increases from 4 °C to 80 °C, the maximum at 266 nm decreased and the 
minimum at 210 nm became less negative. These changes are indicative of the melting of 
the helical segments. The temperature-dependent CD in the presence of Trip 1 and Trip 2 
display the same trend, however, this change is more gradual, particularly between 50 °C 
and 80 °C (Figure 4.3). This is consistent with the stabilization induced by the ligands as 
observed in the UV experiment. 
 A fluorescence quenching experiment was used to further support modulation of 
the σ32 RNA (Figure 4.2d). The oligonucleotide was labeled with a fluorophore on the 5’-
end and a quencher on the 3’-end. Once the RNA is folded, little to no fluorescence is 
observed since the fluorophore and quencher are in close proximity. Upon addition of a 
16 base pair oligonucleotide complementary to the 5’-end, an increase in fluorescence is 
observed, indicating that both ends are further apart in space due to the formation of an 
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open state (Figure 4.2e). Addition of Trip 1 and 2 to this open state structure results in a 
decrease in fluorescence, consistent with reformation of the folded 3WJ state (Figure 
4.2f). The apparent Kd values of Trip 1 and Trip 2 were determined to be 2.5 μM and 1.5 
μM, respectively. 
 
Figure 4.2. Stabilization of a model system RNA by triptycene derivatives 1 and 2. (a) Structures 
of triptycene derivatives, Trip 1 and Trip 2. (b) RNA oligonucleotide used as a model system 
corresponding to a minimal sequence for junction formation. (c) UV thermal melting plots in the 
presence and absence of triptycenes. (d) Schematic of the fluorescence quenching experiment. (e) 
Titration of inhibitor 16 (I16) results in an increase in fluorescence. (f) Titration of Trip 1 or Trip 
2 to the RNA*-I16 complex results in a decrease in fluorescence. 
 
After characterizing Trip 1 and 2 interactions with the model system using 
fluorescence quenching, we turned our attention to the full 5’ region of the σ32 mRNA (-
19 to +229). The 5’ end of the σ32 mRNA was transcribed in vitro for characterization 
using temperature dependent UV and CD techniques. UV thermal melting experiments in 
the presence of Trip 1 and Trip 2 show thermal stabilization of the full length σ32 mRNA 
(-19 to +229, Figure 4.4a). The shift in thermal stabilization is especially prominent in the 
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region between 30 and 60 °C. The CD spectra in the absence and presence of Trip 1 and 
2 are consistent with A-form RNA structure (Figure 4.5). The temperature-dependent CD 
spectra confirm melting of the helical regions of the RNA. Addition of Trip 1 and 2 
results in a more negative peak at 210 nm and a slightly lower maximum at 266 nm, 
indicative of a structural change in the RNA. Thermal stabilization is maximally 
observed between 40 °C and 50 °C and between 60 °C and 80 °C in the presence of the 
triptycenes. 
 
Figure 4.3. Temperature-dependant circular dichroism CD of model system RNA in the absence 
(a) and presence of Trip 1 (b) or Trip 2 (c). 
 
 A reporter assay based on a σ32-GFP fusion protein was developed and used as a 
reporter to monitor responses to cellular stress in E. coli (Figure 4.4b). The rpoH gene, 
which codes for the σ32 protein, along with its promoters were PCR amplified from the 
genomic DNA of E. coli and inserted into a plasmid encoding GFP. Cells were grown at 
30 °C for several hours in the presence or absence of Trip 1 or Trip 2, followed by heat 
shock at 42 °C. Cells containing the control GFP plasmid (no σ32) showed low relative 
GFP fluorescence when grown at 30 °C. An increase in temperature to 42 °C, resulted in 
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a slight increase in fluorescence in the absence and presence of triptycene derivatives 
using the GFP control plasmid (Figure 4.4c). As expected, cells containing the σ32-GFP 
fusion grown at 30 °C showed low fluorescence similar to the GFP control plasmid. 
However, those grown at 42 °C displayed a large increase in GFP fluorescence in the 
absence of compounds. Upon addition of Trip 1 or Trip 2, the relative fluorescence 
decreased to values similar to the control GFP plasmid, indicating a loss of the heat shock 
response. This is consistent with thermal stabilization of the mRNA by the triptycenes, 
where upon an increase in temperature, the structure is more folded and stable, 
suppressing translation of the σ32-GFP fusion protein. Non-specific translational 
inhibition was ruled out using the GFP control plasmid in the presence of Trip 1 or Trip 2. 
 
Figure 4.4. Modulation of σ32 mRNA (-19 to +229)  by triptycene derivatives and targeting σ32 in 
E. coli. (a) UV thermal melting plots in the absence and presence of Trip 1 or Trip 2. (b) Scheme 
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for targeting rpoH using an σ32-GFP fusion protein. (c) Relative fluorescence intensity of GFP 
control and σ32-GFP fusion at 30 °C and 42 °C in the presence and absence of Trip 1 or Trip 2. 
 
 
Figure 4.5. Temperature-dependant circular dichroism CD of σ32 RNA (-19 to +229) in the 
absence (a) and presence of Trip 1 (b) or Trip 2 (c). 
 
Taken together, these experiments demonstrate that triptycene molecules have the 
ability to modulate the structure of the rpoH mRNA. The binding site of triptycene 
molecules as well as the changes in the overall structure of the RNA in the presence of 
ligands can be determined using selective 2’-hydroxyl acylation analyzed by primer 
extension (SHAPE) developed by the Weeks laboratory19. SHAPE is a powerful 
technique used to probe the structure of RNA using electrophilic reagents selectively 
reactive towards the ribose 2’-OH group of conformationally flexible nucleotides. Once 
the RNA has been modified with the SHAPE reagent, mutational profiling (MaP) detects 
SHAPE adducts by the incorporation of noncomplementary bases using a reverse 
transcriptase.20 The cDNA is then analyzed by massive parallel sequencing where 
mutations are analyzed to generate reactivity profiles which are then used to predict the 
RNA structure. A structural analysis of the rpoH mRNA has been reported using 
chemical and enzymatic methods.16 The RNA was treated with 1-cyclohexyl-(2-
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morpholinoethyl)carbodiimide metho-p-toluene sulfonate (CMCT) and diethyl 
pyrocarbonate (DEP), which are selective towards U/G or A, respectively. RNase V1 
enzymatically cleaves the RNA at double stranded regions. Unlike these reagents, 
SHAPE is not sensitive to base sequences allowing for the determination of the overall 
structure without the need to combine several methods. SHAPE has also been used to 
map out small molecule binding sites and conformational changes caused by small 
molecule binding to various RNAs.21,22 This powerful technique would aid in 
determining the sites at which triptycene molecules are binding and imparting 
stabilization of the structure. 
 
Figure 4.6. SHAPE reactivity data. (a) SHAPE reactivity profile produced from the treatment of 
rpoH (-19 to +227) with NMIA (no reactivity = black, high reactivity = red) (b) Mutational rates 
observed in the SHAPE experiment.  
 
We have initiated these studies by treating the RNA with N-methylisatoic 
anhydride (NMIA) at 37 °C. The mutation rate and reactivity profiles demonstrate that 
there are regions with increased reactivity indicated by the red bars (Figure 4.6a,b). 
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Secondary structure prediction from these profiles predicted the structure shown in 
Figure 4.7b. This structure at 37 °C, shows a structure very different from the previously 
reported structure (Figure 4.7).  Previous studies have modified the RNA at 25 °C or 0 
°C. At these temperatures, the RNA is folded in its native consistent with the observed 
decreased translation efficiency of the σ32 protein. At 37 °C, the concentration of σ32 is 
increased due to partial unfolding of the RNA structure. Our results from the SHAPE 
experiment show that the 3WJ formed by region A and region B is no longer present at 
37 °C, adopting a different structure. A comparison of the folded structure at 25 °C and 
our results at 37 °C is shown in Figure 4.7. This structure of the RNA may allow for the 
increased translation efficiency of the σ32 protein. Studies on the RNA structure at 
different temperatures in the presence and absence of triptycene molecules are currently 
underway. These studies will provide insight into the binding mode of triptycenes and 
how they modulate the RNA structure. In cell SHAPE will also be performed to 
determine differences in structure in the presence and absence of triptycenes. 
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Figure 4.7. Comparison of the structure of rpoH (-19 to +227) at 25 °C (a) and the predicted 
structure from SHAPE experiments performed at 37 °C (b). 
 
4.3 Conclusions 
In summary, we have described triptycene-based molecules that modulate the 5’ region 
of the σ32 mRNA temperature sensor from E. coli. Trip 1 and Trip 2 thermally stabilize a 
model system consisting of the critical central 3WJ present in the σ32 mRNA responsible 
for regulation of the heat shock response as determined by UV thermal melting 
experiments and temperature-dependent circular dichroism (CD). UV thermal melting 
experiments on the full 5’ region of the σ32 mRNA also show thermal stabilization. 
Temperature-dependant CD in the presence of ligands confirm this stabilization. To 
determine the triptycenes’ effect on the heat shock response in E. coli, a σ32-GFP fusion 
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protein assay was utilized. In the absence of triptycenes, an increase in fluorescence is 
observed when the cells are heat shocked at 42 °C, indicating σ32 protein translation. 
However, addition of Trip 1 and Trip 2 suppresses fluorescence, consistent with a 
decrease in σ32 protein translation. This new class of small molecules may be important 
tools to study the effects of the heat shock response E. coli. Furthermore, modulation of 
temperature sensing RNA regulatory elements in bacteria could lead to the development 
of novel methods for targeting pathogens or potentiating current antibiotics. Studies are 
underway to investigate these unique applications. 
4.4 Material and Methods 
General Methods: The σ32 mRNA model system (5’-
GGCACAAACGCAACACUGCAUUACCAUGCGGUUGUGCC-3’), Inhibitor 16 (I16) 
(5’-GTGTTGCATTTGTGCC-3’) and all other oligonucleotides were purchased from 
Integrated DNA Technologies (IDT). HPLC-purified σ32 mRNA model system modified 
with a 5’-FAM and a 3’-IowaBlack was also purchased from IDT. E. coli genomic DNA 
was purchased from Addgene (Cambridge, MA USA). Restriction enzymes and T4 DNA 
ligase were purchased from New England BioLabs. T7 RNA polymerase was purchased 
from Promega (Madison, WI USA).Milli-Q (18 MΩ) water was used for all solutions 
(Millipore; Billerica, MA, USA).  
Ultraviolet absorption spectroscopy and thermal denaturation experiments were 
performed on a JASCO V-650 spectrophotometer (JASCO Analytical Instruments; 
Easton, MD, USA) equipped with a JASCO PC-734R multichannel Peltier using quartz 
cells with 1 cm path lengths. Circular dichroism experiments were performed on a 
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JASCO J-1500 CD Spectrometer (Easton, MD, USA) using a 0.1 cm path length quartz 
cuvette. Fluorescence measurements were collected on a Tecan M1000 plate reader 
(Mannedorf, Switzerland). Polymerase chain reaction (PCR) was run on a BioRad C1000 
Touch Thermocycler. 
Synthesis: Trip 1 and Trip 2 were synthesized according to previously described 
methods.181 
Synthesis of rpoH mRNA -19 to +229: Plasmid pRSET-EmGFP (HA EmGFP 
ABC2 V94F) was used for cloning into the XbaI and EcoRI restriction sites. The rpoH (-
19 to 229) gene was obtained by PCR amplification from genomic DNA from E. coli K-
12. The forward and reverse primers used were 5’-
GATCTAGAATCGATTGAGAGGATTTGAATG-3’ and 5’-
GAGAATTCCCGCCTGTGGCAGGCCATAGC-3’, respectively. The pRSET-EmGFP 
plasmid was digested with XbaI and EcoRI then gel purified to isolate the linear vector. 
The σ32 (-19 to 229) PCR product was also digested and inserted into the plasmid using 
T4 DNA ligase. The resulting plasmid was verified by DNA sequencing using a T7 
primer. 
 The DNA template was prepared for transcription by linearization with EcoRI 
then gel purified. The RNA was transcribed in vitro by T7 RNA polymerase (Promega). 
In vitro transcription reactions were set up using the protocol supplied by Promega with 
1X transcription buffer, 10 mM DTT, 0.5 mM each rNTP, and 2-5 μg DNA. 
UV Thermal Denaturation: Model system RNA was suspended at 1 µM in 10 
mM sodium phosphate buffer, pH 7.2 and annealed by heating to 90°C for 5 min, cooled 
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to room temperature slowly, then to 4 °C. Samples were incubated for 1 hour at room 
temperature with 1 µL of ligand at a final concentration of 2 μM. σ32 RNA (-19 to +229) 
was suspended at 0.25 µM in 10 mM sodium phosphate buffer, pH 7.2 and annealed by 
heating to 65°C for 5 min, cooled to room temperature slowly, then to 4 °C.  Samples 
were incubated for 1 hour at room temperature with 1 µL of ligand at a final 
concentration of 2.5 μM. Denaturation was recorded at 260 nm from 20 °C to 90 °C with 
a heating rate of 0.5 °C min-1.  
Fluorescence quenching experiments: All binding experiments were conducted 
in 50 mM sodium phosphate buffer, pH 7.2. Fluorescence measurements were recorded 
with excitation at 495 nm and emission at 520 nm using 5 nm bandwidths. Inhibitor 
strand binding curves were obtained by adding 1 μL of increasing concentrations of 
inhibitor strand to 19 μL of 120 nM RNA. Samples were incubated for 2 hours and ran in 
triplicate in a 384-well plate. Inhibitor strand displacement curves were obtained by 
incubating 120 nM RNA with 1.4 μM inhibitor 16 for 2 hours, followed by addition of 
increasing concentrations of Trip 1 or Trip 2. Samples were incubated for 2 hours and 
measured in triplicate. 
Circular Dichroism: Model system RNA was suspended at 5 µM in 10 mM 
sodium phosphate buffer, pH 7.2 and annealed by heating to 90°C for 5 min, cooled to 
room temperature slowly, then to 4 °C. Spectra were measured every 1 nm between 350 
nm and 200 nm with a 16 s averaging time. Samples containing ligand were incubated 
with Trip 1 or Trip 2 (10 µM) at room temperature for 1 hour. Samples were incubated at 
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each temperature for 20 minutes prior to scan. All CD spectra were buffer corrected and 
converted to molar ellipticity.  
σ32 mRNA (-19 to +229) was suspended at 0.5 µM in 10 mM sodium phosphate 
buffer, pH 7.2 and annealed by heating to 65°C for 5 min, cooled to room temperature 
slowly, then to 4 °C. Spectra were measured every 1 nm between 350 nm and 200 nm 
with a 16 s averaging time. Samples containing ligand were incubated with Trip 1 or Trip 
2 (5 µM) at room temperature for 1 hour. Samples were incubated at each temperature for 
20 minutes prior to scan All CD spectra were buffer corrected and converted to molar 
ellipticity.  
EmGFP-σ32 Plasmid Construction: Plasmid pRSET-EmGFP (HA EmGFP 
ABC2 V94F) was used for cloning into the XbaI and EcoRI restriction sites. The rpoH 
gene was obtained by PCR amplification from genomic DNA from E. coli K-12. This 
included four rpoH promoters (p2, p3, p4, and p5). The forward and reverse primers used 
were 5’-GATCTAGAGAACTTGTGGATAAAATCACG-3’ and 5’-
GAGAATTCGGATCCTTACGCTTCAATGGCAGCAC-3’, respectively. The pRSET-
EmGFP plasmid was digested with XbaI and EcoRI then gel purified to isolate the linear 
vector. The rpoH PCR product was also digested and inserted into the plasmid using T4 
DNA ligase. The resulting plasmid was verified by DNA sequencing using a T7 primer. 
EmGFP σ32 Assay: E.coli DH5α cells transformed with the σ32-EmGFP plasmid 
were grown overnight at 30 °C in Luria broth (LB) supplemented with 50 μg/mL 
ampicillin. Overnight cultures were diluted 1:100 in LB. Triptycenes were added at a 
final concentration of 25 μM. Samples were allowed to grow at 30 °C for 3 hours. 
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Cultures were kept at 30 °C or heat shocked at 42 °C for 18 hours. Optical density was 
measured at 600 nm. Fluorescence was measured by excitation at 486 nm and emission at 
535 nm. Measurements were made in triplicate for each sample. The raw fluorescence 
intensity was divided by the optical density at 600 nm, which was then normalized.  
SHAPE:20,23 The DNA template for σ32 (-19 to 229) with SHAPE linkers 
(described by Weeks et al.) was prepared by PCR amplification from genomic DNA from 
E. coli K-12. The forward and reverse primers used were 5’- 
TAATACGACTCACTATAGGGGGCCTTCGGGCCAAATCGATTGAGAGGATTTG
AATGACTG -3’ and 5’- 
GAACCGGACCGAAGCCCGATTTGGATCCGGCGAACCGGATCGACCGCCTGTG
GCAGGCCATAGC -3’, respectively. The RNA was transcribed in vitro as described 
above. For SHAPE adduct formation, 5 pmol of RNA was heated to 65 °C for 5 min, 
placed on ice, and folded in 100 mM HEPES, pH 8.0, 100 mM NaCl, and 10 mM MgCl2. 
RNA was modified in the presence of 10 mM NMIA for 45 minutes at 37 °C. No reagent 
control was treated with DMSO. The modified RNA was ethanol precipitated and 
subjected to reverse transcription using SuperScript II (Invitrogen) at 42 °C for 3 hours. 
Reverse transcription buffer was composed of 0.7 mM dNTPs, 50 mM Tris-HCl, pH 8.0, 
75 mM KCl, 6 mM MnCl2 and 14 mM DTT. The generated cDNA was ethanol 
precipitated and PCR amplified. DNA libraries were prepared for sequencing on an Ion 
Torrent PGM. Sequencing results were analyzed using ShapeMapper. 
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Chapter 5 : Bridge-head substituted triptycenes for rapid diversification of nucleic 
acid junction binders 
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5.1 Introduction 
Nucleic acid junctions are important structural intermediates in biology.1-3 
Junctions are present in important biological processes including replication.4,5 They also 
occur in viral genomes in addition to trinucleotide repeat expansions associated with 
numerous neurodegenerative diseases.6-12 These structures are also present in 
nanostructures and aptamer-based sensing.13-20 Small molecule modulation of nucleic 
acid structure is a critical process in biological systems. The ability to selectively 
modulate a subset of nucleic acid structures using small molecules would allow for the 
chemical control of cellular processes as well as reprogramming of cellular events.21-37 
The ability to differentially stabilize predefined nucleic acid structures or to reprogram 
and bias the equilibrium distribution of an ensemble of structures in a precise manner 
would have profound impacts not only in biology, but also in nucleic acid 
nanotechnology and material applications. 
We have previously shown that triptycene-based molecules have the ability to 
bind to three-way junctions.38 Additionally, we have shown that these molecules bind to 
d(CAG)·(CTG) repeats implicated in triplet repeat expansion diseases.39 The ability to 
synthesize libraries of triptycene derivatives on solid support will accelerate efforts to 
identify biologically relevant nucleic acid junction binders and will provide further 
insight into the molecular recognition of triptycenes toward diverse junction sequences 
and topologies. To facilitate immobilization, a point of attachment on triptycene is 
needed and the bridgehead position provides a strategic location positioned furthest from 
the sites of diversification (Figure 5.1). 
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Figure 5.1. (a) Schematic of a three-way junction and triptycene core molecule. (b) Triptycene 
building blocks for the immobilization strategy. These may be used to generate triptycene 
mircroarray, put on solid phase synthesis, and used as pull-down probes. 
 
Here, we have synthesized bridge-head substituted triptycenes by utilizing a Heck 
reaction and immobilized them on resin for solid phase synthesis. Several derivatives 
were made and evaluated for binding to a d(CAG)·(CTG) repeat junction using a 
fluorescence-quenching experiment. 
5.2 Results and Discussion 
Retrosynthetic analysis showed that reduction followed by nitration enables 
simultaneous installation of three amine functional groups on the triptycene scaffold.  
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Figure 5.2. Representative disconnections for triptycene 6d. 
 
Two C-C bonds on the bridgeheads were formed by a Diels-Alder reaction between the 
diene on ring B of anthracene 3 and benzyne as the dienophile (Figure 5.2). Anthracene 3 
could be obtained via a Heck cross-coupling reaction of 9-bromoanthracene 1. To 
synthesize bridge-headed triptycenes, we envisioned a palladium catalyzed coupling to 
yield a substituted anthracene, followed by a Diels-Alder with benzyne. A Heck reaction 
using 9-bromoanthracene and methyl acrylate in the presence of palladium(II) acetate, tri-
o-tolylphosphine, triethylamine in a sealed tube resulted in the desired product 2 in 84% 
yield (Scheme 5.1). When the reaction was run under mild conditions with palladium(II) 
acetate as the catalyst and potassium formate as the hydrogen source, 3 was produced in 
85% yield.40 A Diels-Alder reaction with anthracene 3 and benzyne, which was generated 
in situ using 2-(trimethylsilyl)phenyl trifluoromethanesulfonate and cesium fluoride, 
yielded bridge-head substituted triptycene 4 in 95% yield. Nitration of triptycene resulted 
in hydrolysis of the ester and four major regioisomers (5a-5d) which were not separable. 
Esterification of the crude reaction facilitated separation of the regioisomeric mixture 
using column chromatography. Isomers were identified using heteronuclear multiple 
bond correlation (HMBC) and heteronuclear single quantum coherence spectroscopy 
(HSQC). Triptycene 5d was confirmed by crystallization from chloroform. This isomer 
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was then used in the subsequent transformations. Reduction of the nitro groups to the free 
amine, 6d, was achieved by Pd/C and hydrogen gas. 
Scheme 5.1. Synthesis of bridge-head substituted triptycene. 
 
Triptycene 6d was then treated with Fmoc chloride followed by acid catalyzed 
hydrolysis of the ester to yield protected compound 7d. With this orthogonally protected 
building block in hand, immobilized on resin using 2-chlorotrityl chloride resin was 
achieved. After washing the resin, Fmoc groups on triptycene were deprotected using 
20% piperidine in DMF for 1 hour. Decreased deprotection time led to more byproducts. 
The first amino acid was then coupled using HATU and DIEA overnight. Deprotection 
followed by coupling of the desired amino acid was continued until the final sequence 
was obtained. Deprotection of side chain protecting groups and cleavage from resin were 
performed simultaneously using 9:1:1 TFA:TFE:DCM for 2 hour.  Deprotection of the 
aspargine containing molecule required a longer deprotection time of 4 hours. 
Triptycenes were then purified and confirmed by MALDI-MS. 
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Figure 5.3. (a) Synthesis of orthogonally protected building blocks and x-ray crystal structure of 
5d. (b) Solid phase synthesis of triptycene derivatives. i. Fmoc-Trip-OH (7d), DIEA, DCM, 
DMF; ii. 20% piperidine, DMF; iii. Fmoc-His(Trt)-OH, HATU, DIEA, DMF; iv. 20% piperidine, 
DMF; v. Fmoc-Lys(Boc)-OH, HATU, DIEA, DMF; vi. 20% piperidine, DMF; vii. Fmoc-
His(Trt)-OH, HATU, DIEA, DMF; viii. 20% piperidine; ix. TFA:TFE:DCM (9:1:1). 
We evaluated binding of these amino acid substituted triptycenes to a 
d(CAG)·(CTG) repeat junction previously described (Figure 5.4). Among the molecules 
143 
 
previously tested, Trip-(Lys)3 and Trip-(His)3 displayed  the highest affinity towards the 
junction. Several dimeric and trimeric amino acid substituents were synthesized to 
compare with these results. A high-throughput assay in which the 3WJ is labelled with a 
fluorophore and quencher was used to determine binding. Addition of a strand 10 bases 
long complementary to the 5’-end of the junction (I10), opens the structure, resulting in a 
highly fluorescent state (TNR*-I10). Titration of triptycenes will result in a quenching of 
fluorescence if they have the ability to reform the junction (TNR*-Trip). To determine if 
increased flexibility of the amino acid may play an important role in binding, glycine was 
coupled directly to the triptycene core, followed by lysine or histidine. Trip-(Gly-Lys)3, 
8d, displayed increased potency compared to Trip-(Lys)3, indicating that the increased 
flexibility may allow for better binding. Interestingly, Trip-(Gly-His)3, 9d, did not show 
improved binding compared to Trip-(His)3. Trimers were also synthesized composed of 
both lysine and histidine. Trip-(His-Lys-His)3, 10d, and Trip-(His-Lys-Lys)3, 11d, which 
differ in the final amino acid showed comparable binding with Kd = 0.198 μM and 0.169 
μM, respectively. Additionally, the final amino acid was changed to asparagines, 12d, 
and displayed slightly lower binding affinity with a Kd = 0.390 μM. These triptycenes 
were also used in a gel shift assay where the inhibitor strand was incubated with 
unlabeled 3WJ. This results in an electrophoretic shift consistent with a larger complex. 
Titration of triptycene to this complex resulted in reformation of the junction to varying 
degrees (Figure 5.39). 
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Figure 5.4. (a) Schematic of the fluorescence-quenching experiment. (b) Dissociation constants 
of triptycenes determined by the fluorescence assay. 
 
5.3 Conclusions 
In summary, we have prepared bridge-head substituted triptycenes by a rapid 
synthetic method. These building blocks were loaded on resin and subjected to solid 
phase synthesis. Several amino acid derivatives were synthesized and evaluated for 
junction binding using a fluoresence based assay. Most compounds were more potent 
binders than the corresponding monomer amino acids. With these triptycene building 
blocks in hand we have the ability to put them on solid support to generate large libraries 
which can be screened against various relevant junctions for selectivity. Additionally, we 
can generate pull down probes to identify cellular targets. 
5.4 Material and Methods 
General Materials: All commercial reagents and solvents were used as received. 
9-bromoanthracene, potassium formate, nitric acid, Fmoc chloride, pyridine, and 
acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO). Methyl acrylate, 
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triethylamine (Et3N), tri-o-tolylphosphine, palladium(II) acetate, cesium floride, and Pd/C 
were purchased from Acros Organics. Methanol, dichloromethane (DCM), 
dimethylformamide (DMF) were purchased from Fisher Scientific (Waltham, MA). (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide  
hexafluorophosphate) (HATU) was purchased from Oakwood Products, Inc. (West 
Colombia, SC), 2-chlorotrityl resin was purchased from Advanced ChemTech 
(Louisville, KY), diisopropylethylamine (DIEA), trifluoroacetic acid (TFA), and 
tetrafluoroethylene (TFE) were purchased from Alfa Aesar (Ward Hill, MA), and 
piperidine was purchased from American Bioanalytical (Natick, MA). Chloroform-d6, 
methanol-d4, dimethylsulfoxide-d6 were purchased from Cambridge Isotope Laboratories 
(Tewksbury, MA). Thin-layer chromatography was done using Sorbent Technologies 
(Norcross, GA) silica plates (250 µm thickness). Flash chromatography was performed 
on a Teledyne Isco (Lincoln, NE) CombiFlash Rf system using RediSep Rf silica 
columns. 
TNR DNA 3WJ (5’-
GCGGAGCAGCCCTTGGGCAGCACCTTGGTGCTGCTCCGC-3’) and DNA inhibitor 
10 (5’-GCTGCTCCGC-3’) were purchased from Integrated DNA Technologies (IDT). 
HPLC-purified TNR DNA 3WJ oligo modified with a 5’-FAM and a 3’-IowaBlack was 
purchased from IDT. 
 1H and 13C NMR were recorded on a Bruker UNI 500 NMR at 500 and 125 MHz, 
respectively. High resolution mass spectra were obtained at the University of 
Pennsylvania Mass Spectrometry Center on a Waters LC-TOF mass spectrometer (model 
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LCT-XE Premier) using electrospray ionization in positive or negative mode, depending 
on the analyte. High-performance liquid chromatography was performed on a JASCO 
HPLC (Easton, MD) equipped with a Phenomenx (Torrance, CA) column (Analytical: 
Luna 5µ C18(2) 100A; 250 x 4.60 mm, 5 µm Semi-prep: 5µ C18(2) 100A; 250 x 10.00 
mm, 5 µm) using aqueous (H2O + 0.1% CF3CO2H) and organic (CH3CN) phases. Matrix-
assisted laser desorption ionization (MALDI) mass spectra were obtained on a Bruker 
Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA) using α-cyano-4-
hydroxycinnamic acid (CHCA). Fluorescence measurements were collected on a Tecan 
M1000 plate reader (Mannedorf, Switzerland).  
Synthesis: 
 
Methyl-3-(anthracen-9-yl)acrylate (2).182–184 A solution of 9-bromoanthracene (192 
mg, 0.746 mmol), methyl acrylate (642 mg, 7.46 mmol), Et3N (755 mg, 7.46 mmol), tri-
o-tolylphosphine (25 mg, 0.082 mmol), and Pd(OAc)2 (8.37 mg, 0.0373 mmol) in DMF 
(7 mL) was heated at 120 °C in a sealed tube overnight. Upon cooling, the solvent was 
removed under vacuum to give an oil residue that was purified by column 
chromatography on silica gel (5% EtOAc/hexanes) to give 1 (164 mg, 84%). 1H NMR 
(500 MHz, CDCl3) δ 8.65 (d, 1 H, J = 16.3 Hz), 8.45 (s, 1 H), 8.25-8.23 (m, 2 H), 8.03-
8.01 (m, 2 H), 7.53-7.48 (m, 4 H), 6.45 (d, 1 H, J = 16.3 Hz), 3.93 (s, 3 H); 13C NMR 
(500 MHz, CDCl3) δ 167.0, 142.4, 131.4, 129.5, 128.9, 128.4, 126.9, 126.5, 125.5, 125.3, 
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52.07; IR (neat) 3051, 2949, 1719, 1635, 1435, 1265, 1170, 988, 886, 733; HRMS m/z 
calcd for C18H15O2+ [M+H]+ 263.1067, observed 263.1074. 
 
 
Methyl 3-(anthracen-9-yl)propanoate (3).182–184 To a solution of 1 (102 mg, 0.389 
mmol) in DMF (5 mL) was added potassium formate (654 mg, 7.78 mmol) and Pd(OAc)2 
(4.4 mg, 0.02 mmol) and stirred at 60 °C for 4 hours. After cooling, the mixture was 
filtered through Celite and washed with ethyl acetate. The filtrate was washed with water 
and brine, then dried over Na2SO4. The crude mixture was purified by column 
chromatography on silica gel (5% EtOAc/hexanes) to yield 3 (87.3 mg, 85%). 1H NMR 
(500 MHz, CDCl3) δ 8.38 (s, 1 H), 8.28 (dd, 2 H, J = 8.8, 0.6 Hz), 8.02 (dd, 2 H, J = 8.4, 
0.5), 7.56-7.53 (m, 2 H), 7.50-7.46 (m, 2 H), 4.00-3.96 (m, 2 H), 2.82-2.79 (m, 2 H); 13C 
NMR (500 MHz, CDCl3) δ 142.39, 131.36, 129.46, 128.97, 128.4, 126.94, 126.46, 
125.51, 125.32, 52.07; IR (neat) 3053, 2950, 1734, 1436, 1174, 885, 732; HRMS m/z 
calcd for C18H17O2+ [M+H]+ 265.1223, observed 265.1226 
 
 
Methyl 3-(9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (4).185 To a solution of 3 
(443 mg, 1.68 mmol) in acetonitrile (2.8 mL) was added CsF (764 mg, 5.03 mmol) and 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (1.0 g, 3.35 mmol) and stirred at 80 °C 
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for 4 hours. The mixture was concentration under vacuum and extracted with EtOAc and 
saturated NH4Cl. The organic layer was washed with brine and dried over NasSO4. The 
crude mixture was purified by column chromatography on silica gel (5-10% 
EtOAc/hexanes) to yield 4 (542 mg, 95%).1H NMR (500 MHz, CDCl3) δ 7.39-7.36 (m, 6 
H), 7.04-6.98 (m, 6 H), 5.36 (s, 1 H), 3.87 (s, 3 H), 3.36 (t, 2 H, J = 7.2), 3.21 (t, 2 H, J = 
7.2); 13 C NMR (500 MHz, CDCl3) δ 174.7, 147.0, 125.2, 125.1, 123.8, 122.1, 54.6, 53.4, 
52.2, 30.7, 22.7; IR (neat) 2952, 1733, 1450, 1176, 628;  HRMS m/z calcd for 
C24H20NaO2+ [M+Na]+ 363.1356, observed 363.1369. 
 
 
 
 
Methyl 3-(trinitro-9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (5a-d). A 
solution of 4 (424.5 mg, 1.25 mmol) in concentrated HNO3 (15 mL) was stirred at 75 °C 
overnight. The solution was cooled to room temperature, added to water, and stirred. The 
precipitate was collected, washed with cold water, and dried. The crude mixture was then 
reesterified by stirring in methanol (50 mL) with catalytic H2SO4 under reflux overnight. 
The solution was concentrated under vacuum. Water was added and then basified by the 
addition of 1M NaOH. The water was extracted with EtOAc immediately. The organic 
layer was washed with brine and dried over Na2SO4. The crude mixture was purified by 
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column chromatography on silica gel (30% EtOAc/hexanes) to give 5a (110 mg, 19%), 
5b (130 mg, 22%), 5c (37.2 mg, 6.3%), and 5d (88.3 mg, 15%). 5a 1H NMR (500 MHz, 
CDCl3) δ 8.32 (d, 2 H, J = 1.3 Hz), 8.28 (s, 1 H), 8.01 (dd, 3 H, J = 8.3, 2.2 Hz), 7.69 (d, 
1 H, J = 8.1 Hz), 7.62 (d, 2 H, J = 8.4 Hz), 5.87 (s, 1 H), 3.91 (s, 3 H), 3.52 (t, 2 H, J = 
7.4 Hz), 3.17 (t, 2 H, J = 7.4 Hz); 13C NMR (500 MHz, CDCl3) δ 173.4, 146.2, 146.1, 
145.8, 125.2, 123.6, 122.5, 122.1, 119.4, 54.82, 53.27, 52.68, 30.22, 22.04; IR (neat) 
2953, 1734, 1523, 1344, 1201, 738; HRMS m/z calcd for C24H18N3NaO8+ [M+Na]+ 
498.0908, observed [M+Na]+ 498.0919; mp 143-146 °C; 5b 1H NMR (500 MHz, CDCl3) 
δ 8.31-8.29 (m, 3 H), 8.01-7.99 (m, 3 H), 7.69 (d, 2 H, J = 8.1 Hz), 7.64 (d, 1 H, J = 8.4 
Hz), 5.88 (s, 1 H), 3.92 (s, 3 H), 3.56 (t, 2 H, J = 7.3 Hz), 3.20 (t, 2 H, J = 7.3 Hz); 13C 
NMR (500 MHz, CDCl3) δ 173.4, 150.9, 146.2, 145.7, 125.2, 122.4, 122.1, 119.4, 118.1, 
54.6, 53.4, 52.7, 30.2, 21.8; IR (neat) 1733, 1520, 1342, 1201, 736; HRMS m/z calcd for 
C24H18N3NaO8+ [M+Na]+ 498.0908, observed [M+Na]+ 498.0919; mp 139-142 °C; 5c 1H 
NMR (500 MHz, CDCl3) δ 8.32 (d, 3 H, J = 2.2 Hz), 8.03 (dd, 3 H, J = 8.4, 2.2 Hz), 7.60 
(d, 3 H, J = 8.4 Hz), 5.79 (s, 1 H), 3.92 (s, 3 H), 3.48 (t, 2 H, J = 7.6 Hz), 3.13 (t, 2 H, J = 
7.6 Hz); 13C NMR (500 MHz, CDCl3) δ 173.4, 149.9, 146.7, 146.4, 123.7, 122.2, 119.5, 
55.2, 53.6, 52.7, 30.5, 22.6; 5d 1H NMR (500 MHz, CDCl3) δ 8.30 (d, 3 H, J = 1.7 Hz), 
8.04 (dd, 3 H, J = 8.1, 1.8 Hz), 7.63 (d, 3 H, J = 8.1Hz), 5.78 (s, 1 H), 3.96 (s, 3 H), 3.57 
(t, 2 H, J = 7.3 Hz), 3.20 (t, 2 H , J = 7.3 Hz); 13 C NMR (500 MHz, CDCl3) δ 173.36, 
150.51, 146.41, 125.15, 122.49, 118.25, 54.63, 53.80, 52.91, 30.26, 21.82; IR (neat) 
1736, 1525, 1343; HRMS m/z calcd for C24H18N3NaO8+ [M+Na]+ 498.0908, observed 
[M+Na]+ 498.0910; mp 147-150 °C.  
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Methyl 3-(2,7,15-triamino-9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (6d). 
To a solution of 5d (259 mg, 0.544 mmol) in methanol was added Pd/C (25 mg). The 
solution was purged with a H2 gas balloon and kept under H2 gas for 1 hour. The mixture 
was filtered through Celite and washed with methanol. The filtrate was concentrated and 
purified by column chromatography on silica gel (5% MeOH/DCM) to give 6d (204 mg, 
97%). 1H NMR (500 MHz, MeOD) δ 7.01 (d, 3 H, J = 7.7 Hz), 6.79 (d, 3 H, J = 1.7 Hz), 
6.33 (dd, 3 H, J = 7.7, 1.5 Hz), 4.98 (s, 1 H), 3.85 (s, 3 H), 3.18-3.13 (m, 4 H); 13C NMR 
(500 MHz, MeOD) δ 176.48, 144.55, 140.65, 124.09, 112.56, 112.15, 54.23, 53.27, 
52.49, 31.42, 23.83; IR (neat) 3354, 2951, 1724, 1605, 1473, 1326, 1181, 582 HRMS m/z 
calcd for C24H24N3O2+ [M+H]+ 386.1863, observed 386.1848. 
 
 
3-(2,7,15-tris((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9,10-
[1,2]benzenoanthracen-9(10H)-yl)propanoic acid (7d). To a solution of 6d (116 mg, 
0.301 mmol) in DCM (2.5 mL) was added excess pyridine. The solution was cooled to 0 
°C, then added Fmoc chloride in DCM (2.5 mL) slowly. The solution was allowed to 
warm to room temperature over time and stirred overnight. The mixture was extracted 
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with DCM and acidic water. The organic layer was washed with brine and dried over 
MgSO4. The crude mixture (209 mg, 0.199 mmol) was dissolved in dioxane (5 mL), H2O 
(5 mL), and catalytic H2SO4 was stirred at 80 °C overnight. The reaction mixture was 
neutralized and concentrated under vacuum. Water was added to the mixture and was 
extracted with DCM. The organic layer was washed with brine and dried over Na2SO4. 
The crude mixture was purified by column chromatography on silica gel (50% 
EtOAc/hexanes) to yield 8d (165 mg, 80%). 1H NMR (500 MHz, DMSO) δ 12.44 (bs, 1 
H), 9.58 (s, 3 H), 7.89 (d, 6 H, J = 7.6 Hz), 7.72 (d, 6 H, J = 7.0 ), 7.50 (bs, 3 H), 7.40 (t, 
6 H, J = 7.4 ), 7.32 (t, 6 H, J = 7.3 ), 7.27 (d, 3 H, J = 7.9 ), 5.37 (s, 1 H), 4.44 (d, 6 H, J = 
6.7 ), 4.28 (t, 3 H, J = 6.7), 3.04 (m, 4 H); 13C NMR (500 MHz, DMSO) δ 174.2, 153.4, 
143.7, 141.4, 140.8, 135.7, 127.6, 127.1, 125.1, 123.2, 120.1, 65.5, 52.2, 50.9, 46.6, 29.2, 
22.2; IR (neat) 1709, 1605, 1528, 1450, 1212, 738; HRMS m/z calcd for C69H52N3O8+ 
[M+H]+ 1038.3749, observed [M+H]+ 1038.3737; mp 169-171 °C. 
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Figure 5.5. 1H NMR of anthracene 2 in CDCl3. 
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Figure 5.6. 13C NMR of anthracene 2 in CDCl3. 
 
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. 1H NMR of anthracene 3 in CDCl3. 
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Figure 5.8. 13C NMR of anthracene 3 in CDCl3. 
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Figure 5.9. 1H NMR of triptycene 4 in CDCl3. 
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Figure 5.10. 13C NMR of triptycene 4 in CDCl3. 
 
158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. 1H NMR of triptycene 5a in CDCl3. 
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. 13C NMR of triptycene 5a in CDCl3. 
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Figure 5.13. HMBC spectrum of 5a in CDCl3 
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Figure 5.14. Expanded HMBC spectrum of 5a in CDCl3. 
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Figure 5.15. HSQC spectrum of 5a in CDCl3. 
. 
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Figure 5.16. Expanded HSQC spectrum of 5a in CDCl3. 
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Figure 5.17. 1H NMR of 5b in CDCl3. 
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Figure 5.18. 13C NMR of 5b in CDCl3. 
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Figure 5.19. HMBC spectrum of 5b in CDCl3. 
. 
 
 
 
167 
 
 
 
Figure 5.20. Expanded HMBC spectrum of 5b in CDCl3. 
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Figure 5.21. HSQC spectrum of 5b in CDCl3. 
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Figure 5.22. Expanded HSQC spectrum of 5b in CDCl3. 
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Figure 5.23. 1H NMR of 5c in CDCl3. 
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Figure 5.24. 13C NMR of 5c in CDCl3. 
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Figure 5.25. HMBC spectrum of 5c in CDCl3. 
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Figure 5.26. Expanded HMBC spectrum of 5c in CDCl3. 
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 Figure 5.27. HSQC spectrum of 5c in CDCl3. 
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Figure 5.28. Expanded HSQC spectrum of 5c in CDCl3. 
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Figure 5.29. 1H NMR of 5d in CDCl3. 
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Figure 5.30. 13C NMR of 5d in CDCl3. 
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Figure 5.31. HMBC spectrum of 5d in CDCl3. 
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Figure 5.32. Expanded HMBC spectrum of 5d in CDCl3. 
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Figure 5.33. 1H NMR of 6d in MeOD. 
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Figure 5.34. 13C NMR of 6d in MeOD. 
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Figure 5.35. 1H NMR of 7d in DMSO. 
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Figure 5.36. 13C NMR of 7d in DMSO. 
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Solid Phase Synthesis: All triptycenes were synthesized on 2-chlorotrityl resin 
(100-200 mesh, 1.5 mmol substitution/g). The resin was added to a dry glass reaction 
vessel and swollen by stirring in dichloromethane (DCM) for 30 minutes. After swelling, 
the DCM was removed by vacuum and Fmoc-Trip-OH was coupled to the resin. Fmoc-
Trip-OH (1.5 equiv) in 1:5 DMF:DCM and DIEA (5equiv) were added and stirred for 5 
minutes. DIEA (1.5 equiv) was added and the resin was stirred overnight. The solution 
was then drained by vacuum and the resin was washed thoroughly with DMF, then DCM, 
then DMF. The beads were deprotected by treatment with 20% piperidine in DMF for 1 
hour with stirring.  The deprotection solution was removed by vacuum and the resin was 
washed thoroughly with DMF, DCM, then DMF. The first Fmoc-protected amino acid 
was then activated with HATU (9 equiv) in the presence of DIEA (18 equiv) prior to 
addition to the reaction vessel and allowed to couple overnight. Subsequent deprotections 
and amino acid couplings were run as described above. Before cleavage from the resin, 
the terminal Fmoc was removed. The beads were thoroughly washed with DMF then 
DCM. Peptides were cleaved by addition of trifluoroacetic acid (TFA), 
tetrafluoroethylene (TFE), and DCM (9:1:1). The cleavage solution was collected by 
vacuum and concentrated using a rotary evaporator. The crude residue was diluted in 1:1 
(0.1% TFA/H2O:MeCN), purified by reverse-phase HPLC, and analyzed by MALDI-MS. 
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Figure 5.37a. Analytical HPLC chromatogram of Trip-(Gly-Lys)3 (8d). HPLC chromatograms 
were obtained at all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were 
used to show absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
 
  
Figure 5.37b. Analytical HPLC chromatogram of Trip-(Gly-His)3 (9d). HPLC chromatograms 
were obtained at all wavelengths from 200 to 800 nm (bottom plot). Two virtual channels were 
used to show absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
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Figure 5.37c. Analytical HPLC chromatogram of Trip-(His-Lys-His)3 (10d). HPLC 
chromatograms were obtained at all wavelengths from 200 to 800 nm (bottom plot). Two virtual 
channels were used to show absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
 
  
Figure 5.37d. Analytical HPLC chromatogram of Trip-(His-Lys-Lys)3 (11d). HPLC 
chromatograms were obtained at all wavelengths from 200 to 800 nm (bottom plot). Two virtual 
channels were used to show absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
NH
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Figure 5.37e. Analytical HPLC chromatogram of Trip-(His-Lys-Asn)3 (12d). HPLC 
chromatograms were obtained at all wavelengths from 200 to 800 nm (bottom plot). Two virtual 
channels were used to show absorbances at 254 nm (blue) and 214 nm (red) (top plot).  
 
Table 5.1. Calculated and observed triptycene masses. 
 
 
Fluorescence Quenching Assay: All experiments were conducted in 50 mM 
sodium phosphate buffer, pH 7.2. Fluorescence measurements were recorded with 
excitation at 495 nm and emission at 520 nm using 5 nm bandwidths on a Tecan M1000 
plate reader. Inhibitor strand displacement by triptycene curves were obtained by 
incubating 120 nM TNR DNA with 10 μM inhibitor 10 for 2 hours, followed by addition 
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of increasing concentrations of triptycenes. Samples were incubated for 2 hours and 
measured in triplicate in a 384-well plate. 
 
Figure 5.38. Fluorescence-quenching experiment plots. Displacement of I10 from TNR 3WJ by 
Trip-(Gly-Lys)3 (a), Trip-(Gly-His)3 (b), Trip-(His-Lys-His)3 (c), Trip-(His-Lys-Lys)3 (d), Trip-
(His-Lys-Asn)3 (e). 
 
Gel Shift Assay: Gel shift experiments were conducted in 50 mM sodium 
phosphate buffer, pH 7.2. Triptycene titration gels were prepared by incubating TNR 
3WJ (0.5 μM) with inhibitor strand 10 (1.5 μM) for 2 hours followed by titration of 
triptycenes and incubation at room temperature for 2 hours. Samples were loaded on a 
20% non-denaturing polyacrylamide gel (19:1 monomer:bis) at 50V in 1X TBR buffer at 
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4°C for 10 hours. Gels were imaged by staining with SYBR Gold for 15 minutes then 
visualized using a BioRad GelDoc XR+ imager. 
 
 
Figure 5.39. Gel shift assay in the presence of triptycenes. TNR 3WJ was incubated with I10 
followed by titration of triptycene derivatives, Gly-Lys (a), Gly-His (b), His-Lys-His (c), His-
Lys-Lys (d), or His-Lys-Asn (e). 
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Table 5.3.  Summary of Structure Determination of 5d. 
Empirical formula  C25H18N3O8Cl3 
Formula weight  594.77 
Temperature  100(1) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  C2/c       
Cell constants:   
a  29.8039(12) Å 
b  9.4923(4) Å 
c  22.1375(9) Å 
 120.796(2)° 
Volume 5379.8(4) Å3 
Z 8 
Density (calculated) 1.469 Mg/m3 
Absorption coefficient 0.394 mm-1 
F(000) 2432 
Crystal size 0.25 x 0.12 x 0.10 mm3 
Theta range for data collection 1.59 to 25.40° 
Index ranges -35 ≤  h ≤  32, -11 ≤  k ≤  11, -26 ≤  l ≤  26 
Reflections collected 39795 
Independent reflections 4911 [R(int) = 0.0251] 
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Completeness to theta = 25.40° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.7055 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4911 / 0 / 345 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0335, wR2 = 0.0855 
R indices (all data) R1 = 0.0400, wR2 = 0.0897 
Largest diff. peak and hole 0.412 and -0.525 e.Å-3 
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Chapter 6 : Conclusion and future directions 
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The ability to selectively modulate a particular nucleic acid structure would allow 
for the precise control of cellular processes at the DNA or RNA level; however this has 
remained a significant challenge. Nucleic acid junctions are ubiquitous motifs found in 
DNA and RNA involved in important biological processes. Three-way junctions (3WJs) 
are formed at the interface of three double-helical DNA or RNA strands forming a Y-
shape with a hydrophobic cavity in the center and varying degrees of flexibility. These 
junctions are present in a number of important biological processes including replication 
and recombination. They are also found in triplet repeat expansions, bacterial mRNA 
temperature sensors, and viral genomes. Modulation of these junctions with small 
molecules could aid in the development of new tools or strategies for the regulation of 
biological processes. We have developed a new class of small molecule junction binders 
based on triptycene that have the ability to discriminate 3WJs over other double helical 
structures.   
We initially evaluated triptycene binding using a designed 3WJ. Nucleic acid 
junctions were significantly stabilized in the presence of triptycene molecules. This 
stabilizing effect was not observed with other DNA secondary structures, confirming that 
triptycene preferentially binds to 3WJs. This was then confirmed on a well-studied 3WJ 
using several methods such as UV thermal denaturation, circular dichroism (CD), 
fluorescence-quenching, and a gel shift assay.  
After validating our hypothesis, we applied these molecules to biologically 
relevant junctions. Expansions of repetitive nucleic acid sequences, such as 
(CAG)·(CTG) have been implicated in neurodegenerative diseases such as Huntington’s 
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and myotonic dystrophy. We have shown that triptycene molecules have the ability to 
bind to d(CAG)·(CTG) repeats. These small molecules may be used as probes to study 
disease mechanisms associated with trinucleotide repeat expansions. Binding of these 
ligands may affect repair outcomes of proteins recruited to these junctions.  
We then investigated triptycene binding to RNA 3WJs. We focused on a perfectly 
paired 3WJ present in a bacterial temperature sensor involved in the heat shock response 
in E. coli. The induction of heat shock proteins in E. coli is regulated by σ32 which is 
encoded by the rpoH gene. The rpoH mRNA contains a 3WJ that is necessary for the 
induction of the σ32 protein. We have shown that triptycenes thermally stabilize a model 
system composed of a minimal sequence to form the 3WJ as well as the full regulatory 
region. Additionally, a reporter assay using emerald green fluorescent protein (EmGFP) 
fused to σ32 was developed to monitor cellular stress in E. coli. In the presence of 
triptycenes, the heat shock response is decreased, as observed by the decrease in 
fluorescence. These molecules may provide a basis for a new class of antibacterial agents 
or antibiotic adjuvants and could also provide insight into fundamental biology of the 
heat shock response. 
The interaction between triptycene molecules and the rpoH mRNA is currently 
being investigated. The RNA structure of rpoH (-19 to 227) is being probed using 
SHAPE chemistry developed by the Weeks laboratory to gain insight into the RNA 
structure at different temperatures in the presence and absence of triptycenes. The in vitro 
transcribed mRNA will be treated with a SHAPE reagent in the presence and absence of 
triptycene derivatives in order to determine regions to which it binds and how they may 
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affect the overall structure of the RNA. These experiments can also be performed at 
various temperatures to determine the stability of the RNA in the presence and absence of 
RNA binding compounds. In vivo SHAPE experiments can be performed in E. coli cells 
to determine the effects of RNA binding in the context of a native, molecularly crowded, 
biological environment. Another interesting area is the interplay between the bacterial 
heat shock response, antibiotic action, and the evolution of antibiotic resistance. Minimal 
inhibitory concentration (MIC) of the RNA binders in the presence and absence of 
clinically relevant antibiotics will be determined to investigate their antibacterial activity 
and potential synergistic effects for use as antibiotic adjuvants. Mutational rates of the 
bacteria can also be determined in the presence of triptycene heat shock modulators, 
which may allow for the elucidation of their target in vivo.  
The ability to synthesize large libraries of triptycene derivatives would allow for 
screening of numerous biologically relevant junctions. This would also allow us to gain 
further insight into the molecular recognition of triptycenes towards various junctions 
including perfectly paired or those containing bulge bases at the junction interface. In 
order to generate these libraries, a point of attachment of the triptycene core is necessary 
to allow for immobilization on solid support. We have synthesized bridge-head 
substituted triptycene derivatives and successfully immobilized them on resin for 
diversification by solid phase synthesis. Di- and tri-peptide containing triptycenes were 
synthesized on solid phase and evaluated for binding to d(CAG)·(CTG) repeat junction 
described previously. 
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With these bridge-head substituted triptycenes, we now have the ability to quickly 
synthesize large libraries for diversification. These will be immobilized on microarrays 
and screened again biologically relevant junctions that are fluorophore- and radio-
labelled. The ability to conduct rapid high-throughput diversification of triptycenes using 
solid phase approaches will expedite the synthesis of large triptycene libraries, allowing 
the identification of junction specific triptycene molecules with high levels of sequence 
and topological discrimination. This approach will be used to identify small molecules 
that bind to junctions present in viral genomes, including HIV, HCV, and adenovirus, as 
well as improved binders towards trinucleotide repeat junctions and the rpoH mRNA 
junction.   Additionally, junction specificity may be addressed, in which molecules may 
be developed to preferentially target perfectly paired junctions, single and multiple 
bulged junctions, specific sequences at the interface, as well as discrimination between 
DNA and RNA. A junction specific molecule would minimize off-target effects.  
Bridge-head substituted triptycenes will also allow for the synthesis of pull down 
probes with the most promising molecules. Pull down experiments can be joined with 
high-throughput sequencing methods to characterize the triptycene targets. These 
reagents may use biotin as a handle and can be noncovalent or may contain crosslinkers 
on the arms of the triptycene. These probes will be used in bacterial cells as well as 
human cell lines to discover molecular targets, off-target effects, and previously unknown 
junctions. 
Crystallization of nucleic acid junctions with various triptycene derivatives has 
been attempted using previously crystallized DNA and RNA 3WJ sequences, although 
199 
 
this has been unsuccessful to date. Structural studies will also be continued to elucidate 
the binding mode of triptycenes, which may aid in the design and development of more 
potent and selective binders. 
 
 
